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Abstract 
 
The aim of this work was to investigate putative biomarkers of neuronal 
plasticity and repair in the central nervous system. The effects of different 
disease processes, such as inflammation, demyelination and 
neurodegeneration were explored.  
 
We developed and validated ELISA-based assays for the quantification of 
neural cell adhesion molecule (NCAM) and growth-associated protein (GAP)-
43, two known facilitators of neuronal outgrowth in the nervous system. NCAM 
isoforms in biological samples were characterised using mass spectrometry. 
Soluble NCAM was measured in in-vitro and in-vivo models of 
inflammation/demyelination and neurodegeneration, and across different 
neurological disorders in the CSF to understand the impact of inflammation and 
axonal loss on its levels. Recombinant GAP-43 was produced using baculovirus 
technology and purified in appreciable amounts for use in a new ELISA. Soluble 
GAP-43 levels were quantified across different neurological disorders in the 
CSF. Values for CSF NCAM and GAP-43 were correlated with clinical outcome 
measures.  
 
CSF NCAM demonstrated a restricted pattern of expression compared to that of 
serum whilst GAP-43 is almost exclusively expressed in the CSF, indicating that 
these biomarkers are intrathecally synthesised. CSF NCAM and GAP-43 levels 
were lower in neurological disorders with prominent axonal injury; multiple 
sclerosis, movement disorders, motor neurone disease, Alzheimer’s disease 
and meningitis. In vitro neuronal cell culture model and in vivo experimental 
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autoimmune encephalomyelitis studies demonstrate that CSF NCAM correlates 
well with disease progression in multiple sclerosis. A similar relationship was 
not found with CSF GAP-43. 
 
In conclusion, the adult CNS may possess the intrinsic capacity to repair, but 
this capacity may be dramatically reduced in disease states. Measuring this 
process may be important in understanding neuronal repair and plasticity.  
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1 General Introduction 
 
1.1 Neurodegenerative diseases: a failure of plasticity and 
repair? 
 
The mechanisms of how physiological regulation of neuronal death and repair 
or plasticity is maintained in the central nervous system (CNS) and importantly 
the transition to pathological neurodegeneration, represent central questions in 
neuroscience. Evidence suggests that neurodegeneration occurs in two ways: 
1) primary degenerative events caused for example by a failure in neuroaxonal 
health owing to a variety of contributory factors, such as extracellular 
accumulation of amyloid-beta protein in Alzheimer’s disease (AD) 1; 2 and 
intracellular alpha-synuclein inclusions in Parkinson’s disease (PD) 3; 4, or 2) 
secondary neurodegeneration following trauma or chronic inflammation 
resulting in axonal transection and Wallerian degeneration, when compensatory 
mechanisms fail, classically observed in conditions such as multiple sclerosis 
(MS) 5 and spinal cord injury 6. In both paradigms the problem remains that 
neurones which are lost in this manner in the adult CNS are unlikely to be 
replaced and recovery is largely dependent on the redundancy in the system as 
well as its capacity for repair 7; 8, posing the question whether 
neurodegeneration is in fact a failure of plasticity and repair? 
 
In fact neuronal death and survival represent one of the fundamental facets of 
brain homeostasis, and although continued neuronal loss is a hallmark of 
neurodegenerative disorders and senescence the extent to which functional 
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impairments correlate directly with neuronal loss is controversial. For instance, 
T2 lesion load on MRI correlate poorly with disability in MS 9. Furthermore, pre-
clinical AD cases resemble mild AD cases pathologically but do not manifest 
cognitive impairment or decline on standard neuropsychometric testing 10. 
Granted, peak clinical performance at later stages of disease is capped by the 
loss of neurones, but there remain striking fluctuations in functional abilities that 
patients experience over time during their illnesses 11. Whether this perceived 
neurological impairment is in fact neurological dysfunction rather than neuronal 
loss or modified by plasticity is difficult to establish, and it is this inability to 
reconcile the myriad of factors involved in disease pathophysiology that has 
prevented the formulation of a unified theory on disease progression which 
remains speculative at present 8; 12. 
 
Neuronal damage almost always triggers compensatory mechanisms and 
neuroplasticity is a generic term referring to processes involved in the structural 
and functional adaptation of the organism to the environment, experience, 
attrition and injury 13. At a molecular level this comprises of alterations in 
dendritic ramifications, axonal sprouting, synaptic remodelling, synaptogensis 
and neurogenesis 14. Barriers to neuroplasticity, loss of plasticity and 
maladaptive plasticity-related cellular events have been postulated as initiators 
of neurodegeneration in both AD 15 and MS 8. In MS the damaging inflammatory 
pathways also triggers regulatory mechanisms that promote tissue repair. For 
instance, pro-inflammatory cytokines interleukin 1β and interferon γ promote in- 
situ apoptosis of encephalitogenic T cells, while TNFα (via TNFRII) stimulates 
remyelination by directing the differentiation and proliferation of myelin-forming 
cells. Encephalitogenic CD4 T cells produce neurotrophic factors including 
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BDNF, neurotrophins 3 and 4/5, while antimyelin antibodies stimulate 
oligodendrocyte proliferation, and macrophages/microglia phagocytise myelin 
debris thereby promoting remyelination 8; 16; 17. However, these counter 
regulatory anti-inflammatory mechanisms become blunted over time, which may 
be due to a decrease in neuroplasticity due to ageing of the repair mechanisms 
themselves. It is postulated that the efficiency of remyelination decreases with 
age; Sim et al. 18 demonstrate a delay in oligodendrocyte precursor recruitment 
and differentiation in old mice compared to young mice.  Following axotomy, 
pronounced axonal sprouting proximal to the injury was found only in young 
mice lacking Nogo A/B (myelin-derived axon growth inhibitor) with a restriction 
at the older ages 19. Whilst older growth cones of axons are repelled during 
regrowth compared to their younger counterparts owing to a decline in growth 
cone responsiveness to external stimuli 20. Clinical presentations of 
neurodegenerative disorders parallel that of experimental data with most 
neurodegenerative disorders becoming apparent in adult life, for example AD, 
MS and PD, likely explaining why age is the single most important risk factor for 
AD. In AD the magnitude and rate of compensatory synaptogenesis following 
injury and the ability to sustain the effects of long-term potentiation (LTP) are all 
slowed or decline progressively with age 21; 22. It is therefore conceivable that 
the physiological cellular plasticity is responsible for alleviating or altering 
symptoms, but may also contribute to the symptoms of neurodegeneration 
through an inability to stimulate repair effectively in an aged environment. 
 
This argument does not hold true if you are a stroke patient, however, who 
despite their advanced age, show recovery in function up to a year after the 
event. Analysis of human stroke tissue demonstrated evidence of early 
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neuronal markers doublecortin (DCX) and β-III tubulin in the ischaemic 
penumbra indicating at least in stroke there is a viable endogenous repair 
mechanism 23. Equally, rodent models in stroke show proliferation of cells within 
the known neurogenic zones, the subgranular zone (SGZ) and the 
subventricular zone (SVZ) and migration of newborn neurones into the 
ischaemic brain regions 24; 25. The acute nature of the insult may be relevant, 
whereas neurodegenerative disease processes normally gather momentum 
over time heightening the burden on neuroplasticity. So again, the idea that 
neurodegeneration may in fact be a counterpart of neuroplasticity warrants 
consideration. 
 
1.1.1 The CNS axon and its response to injury 
 
Spontaneous repair in the adult CNS, in comparison with the peripheral nervous 
system (PNS) or the embryonic nervous system, does not occur as a rule 26; 27. 
In addition, the glial environment of the adult CNS is more likely to be an 
additional barrier to axonal regrowth than to provide assistance 28; 29. Despite 
this permanency in regeneration failure, it has long been recognised that there 
are also variable degrees of compensatory plasticity within lesioned pathways. 
Three distinct types of axonal sprouting have been described following injury; 
regenerative sprouting, collateral sprouting and compensatory sprouting, which 
may occasionally lead to partial recovery of the original function (Figure 1-1) 30.  
Regenerative sprouting refers to the formation of new axonal processes at the 
site of injury shortly after transaction; this has always been an abortive process 
owing to the inhibitory CNS environment and a lack of guidance cues involved 
in axonal pathfinding. Collateral sprouting is sprouting from unlesioned 
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neighbouring fibres into the synaptic space formerly occupied by the transected 
axon. Whereas, compensatory sprouting is the formation of new axonal sprouts 
from the injured axon proximal to the lesion towards neurones neighbouring the 
denervated area.  
 
 
Figure 1-1 Modes of control of axonal regneration following injury to the adult CNS. A) A 
lesioned axon is separated from its original target (on the left). B) Regenerative sprouting 
involves the growth of an axon that has been interrupted but does not lead to reconnection with 
the original target. C) Collateral sprouting involves growth of additional presynaptic arbors from 
somewhere along an existing undamaged axon. D) Compensatory sprouting involves the 
formation of additional collaterals above the level of lesioned axon that acts to increase the 
density of innervations targets rostral to the site of injury. 
 
Axonal sprouting and pathfinding is mediated by the growth cone, the motile tip 
of the growing axon, and is known to be guided by at least four mechanisms: 1) 
contact-mediated attraction, 2) chemo-attraction, 3) contact-mediated repulsion, 
  
      
A 
B C D 
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and 4) chemorepulsion (Figure 1-2) 31. A relatively limited set of guidance 
molecules exist, including the neural cell adhesion molecule immunoglobulin  
 
 
 
 
Figure 1-2 Proposed roles of neural recognition molecules in growth cone guidance. A) 
Contact-mediated attraction over short-range requiring direct cell-cell or cell-substratum contact. 
B) Contact-mediated repulsion over short-range requiring direct cell-cell or cell-substratum 
contact. C) Chemo-attraction over long-range as a result of diffusible factors. D) 
Chemorepulsion over long-range as a result of diffusible factors. 
 
 
 
superfamily (CAMs), the netrins, semaphorins, SLIT family, and the ephrins, all 
of which are highly conserved phylogenetically 32; 33. Most of these guidance 
cues are expressed in the adult CNS, whilst some may be further up-regulated 
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following injury 34. In addition to these classical guidance molecules, another 
class of growth-guidance cues, the growth-associated proteins later 
characterised as one and the same protein: GAP-43 is equally interesting. A 
large body of supportive evidence from in vitro and in vivo work suggests that 
GAP-43 plays an important role in neurite outgrowth by greatly potentiating  
neurite adhesion, sprouting and terminal arborisation, and can therefore be 
considered an intrinsic determinant of nerve growth 35; 36; 37. Trophic influence 
from neurotrophins brain-derived neurotrophic factor (BDNF), nerve growth 
factor (NGF), and neurotrophin (NT)-3,-4, have also been demonstrated to 
stimulate regeneration, remyelination and increase neuronal survival when 
applied exogenously 38; 39; 40; 41; 42. In the PNS following peripheral nerve injury, 
Schwann cells as well as actively phagocytosing myelin debris produce 
neurotrophic factors that support axonal growth. In the CNS, the lack of growth 
factor support may be one of the factors contributing to poor recovery. This and 
the inhospitable milieu of the injured environment strongly perturb axonal 
regrowth. CNS myelin-associated proteins, Nogo-A, myelin-associated 
glycoprotein (MAG), oligodendrocyte-myelin glycoprotein (OMgp) and ephrin-
B3, which normally provide inhibitory guidance cues to axonal pathfinding 
during development, become an additional barrier to axonal regrowth following 
injury 43; 44.  
 
1.1.2 Measuring neuroplasticity: looking to neurodevelopment for 
the answers 
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One of the major challenges facing contemporary neurobiology has been to find 
procedures for measuring neuronal self-protection, plasticity and restoration. 
The adult human brain contains anywhere between 80-90 billion neurones 45, 
which, during development have been carefully guided along specific pathways 
to their intended goals 46. During such migration the growth cone explores the 
surrounding extracellular matrix (ECM) and other cells responding to a wide 
variety of attractive and repelling cues 47. The expression of most guidance 
cues is developmentally regulated but some of them are present in the adult 
nervous system and, or recapitulated following injury (see Figure 1-3). 
Understanding the developmental processes; molecular events underlying the 
differentiation, migration and integration of neuronal connections in the brain, 
may provide insight into neuro-restorative capacity of the adult brain and 
tangible ways of measuring this neurogenic potential. 
 
During development, both NCAM and GAP-43 are abundantly expressed in the 
CNS 35; 48. The spatiotemporal expression of NCAM in the developing brain is 
regulated in manner to suggest involvement in morphogenesis, in establishing 
the precision and topography of neural patterns 49; 50; 51; 52; 53. NCAM is found 
throughout the rat corticospinal axons as they grow from the cortex to the spinal 
cord, with PSA-NCAM becoming evident only later restricted to the distal 
segments coinciding with delayed onset of branching by these axons 54. 
Retinotectal neurones display high levels of PSA-NCAM at periods of high 
plasticity thought to be involved in targeting corrections by these axons, 
evidence from antibodies directed against NCAM support this with
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 Classification of factors regulating neuronal outgrowth in the mammalian nervous system. This list represents a subset of permissive, inhibitory 
and guiding (affecting the advance of the growth cone) environmental cues that direct axons via interactions with the growth cone. BDNF=brain-derived neurotrophic 
factor; CAMs=cell adhesion molecules; CSPGs=chondroitin sulfate proteoglycans; GAP-43=growth associated protein-43; GDNF=glial-derived neurotrophic factor; 
HSPGs=heparan sulfate proteoglycans; MAG=myelin-associated glycoprotein; NCAM=neural cell adhesion molecule; NG2=neuron-glia antigen 2; NT=neurotrophin; 
OMgp=oligodendrocyte-myelin glycoprotein (adapted from Kiryushko et al. 47). 
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the finding that these antibodies distort the retinotectal projection patterns 
greatly reducing their precision 55; 56; 57. NCAM also appears to play a critical 
role in the formation and function of synaptic terminals, in particular the 
mechanisms of recycling synaptic vesicles, wherein high-frequency synaptic 
transmission at neuromuscular junctions is impaired resulting in locomotor 
defects 58. GAP-43 has also been well-researched in the rodent and mammalian 
brain and shown to be present specifically in areas undergoing axonal 
elongation and synapse formation associated with growth cones and immature 
synapses, respectively 59. Convergent data from different sources indicate that 
GAP-43 plays an important role in the maintenance of a functional growth cone 
and its induction may be a pre-requisite for axon growth, whilst also modulating 
the formation of new connections and structural plasticity 35; 59; 60. At a molecular 
level, GAP-43 comprises of 1% of the total protein of growth cone membranes 
in the developing brain and the time course of GAP-43 expression coincides 
with, or slightly precedes initiation of axon growth in regenerating fish and 
amphibian neurones, consistent with the proteins’ involvement in axon 
elongation 37. Elevated GAP-43 expression continues for the duration of axon 
elongation and synaptogenesis in all developing and regenerating systems 
during the ‘critical period’ for plasticity which is anywhere between 2-10 weeks 
after nerve injury 36; 61. Overexpression experiments indicate that GAP-43 
greatly promotes spontaneous sprouting of nerves in their terminal fields 62, 
whilst a lack of GAP-43 leads to defects in neuronal pathfinding during early 
development 63. Considering the effects of these molecules on plasticity during 
development, it would be tempting to speculate that in the mature nervous 
system their re-expression is necessary for structural remodelling of neuronal 
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networks. The ageing brain is characterised by a reduction in brain weight, 
cortical atrophy and neuronal cell loss 64. To avoid functional decline, 
regenerative processes may have to be activated. However, the profound 
neuronal loss and cognitive decline occurring in advanced age imply that these 
mechanisms of plasticity may be particularly vulnerable during the ageing 
process. NCAM converts from the embroyonic PSA-NCAM to the distinct adult 
forms NCAM-180, NCAM-140 and NCAM-120 which carry one third of the sialic 
acid content of the embryonic form and therefore more adhesive with tendency 
toward homophilic binding during maturation 53; 65. In rats, the total NCAM 
content in whole brain remains unchanged from postnatal day 40 to old age, but 
drops during early postnatal development 66. The subunit composition of the 
adult form of NCAM are also known to change with neural cell differentiation 
with the selective expression of NCAM-180 whose lateral mobility within the 
membrane is reduced by the longer cytoplasmic domain and its interaction with 
cytoskeletal-associated proteins 67. NCAM-180 is accumulated in post-synaptic 
densities determining the stability of contacts between pre- and post-synaptic 
membranes and the state of synaptic activity 68. In ageing rodent brains, NCAM-
180 and NCAM-140 (expressed on both pre- and post-synaptic membranes) 
are selectively down-regulated, thus indicating a general decline in remodelling 
capacity during ageing 66; 68. An age-associated decline in GAP-43 expression 
has not been found in experimental models 69; 70, however, regional changes in 
GAP-43 expression have been observed. In the rat hippocampus, an area 
linked with continual synaptic turnover or plasticity, there is an overall reduction 
in GAP-43 mRNA with age, especially in the CA3 region 71. Following seizure 
activity, young and middle-aged rats retain the ability to upregulate GAP-43 
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expression in the hippocampus, while in the old rats this response was 
markedly weakened, suggesting a reduced potential for plasticity here 71.  
 
1.1.3 An approach to quantifying neuroplasticity in the adult CNS 
 
Due to the unavailability of living human brain for biochemical analysis 
considerable efforts have been devoted to the study of cerebrospinal fluid (CSF) 
as a tool for assessing the production of molecules and compounds by the 
CNS. CSF is produced at a rate of 500 ml/day, containing approximately 0.2 g/l 
72 of plasma protein constituting 60% of CSF total protein, with the remainder 
comprising mainly CNS-synthesised proteins 73. These non-plasma proteins are 
largely cytoskeletal components expressed predominantly in neurones and glial 
cells and released into the CSF through destruction or changes in membrane 
permeability, or as by-products of metabolism. Several brain specific proteins 
have been described to date, and include soluble versions of all three major 
isoforms of NCAM as well as GAP-43. CSF NCAM is thought either to arise 
from spontaneous release from the plasma membrane, particularly in the case 
of NCAM-120 following extracellular cleavage by phosphatidylinositol-specific 
phospholipase C 74, or possibly by degradation of the extracellular matrix or 
active secretion 75. The synaptic protein GAP-43 has been shown to be 
preferentially released from damaged brain tissue during neuronal necrosis 76. 
Their functional role in the CSF remains a mystery, with claims for a regulatory 
role or simply waste products from the nervous system. Alterations in CSF 
NCAM and GAP-43 have been described in various neurological disorders 
(Table 1-1), whether their CSF profile can become representative of 
neuroplasticity is yet to be demonstrated.  
 
 
28 
 
1.2 Multiple Sclerosis: a model for the study of neuroplasticity 
 
MS is an autoimmune disorder where characteristically both inflammation and 
neurodegeneration coexist to greater and lesser degrees creating 
heterogeneity. Activated immune cells enter the brain via the blood brain barrier 
(BBB), facilitated by the disruption of the BBB by inflammatory cytokines and 
chemokines 77. Once inside, these activated immune cells react to putative 
autoantigens, which include myelin basic  protein (MBP) and myelin 
oligodendrocyte protein (MOG) leading to demyelination 78. Over time, a self-
sustaining autoimmune reaction to these putative autoantigens may ultimately 
be established despite attempts to mitigate this by local regulatory factors. Both, 
T-cells and B-cells have been found in MS brain lesions and CSF of MS 
patients and felt to be directly involved in the pathogenesis of the disease, but 
only recently the discovery of meningeal B-cell follicles proffers a way to 
understanding the maintenance of lymphoid activity in the chronic stages of the 
disease 79.  
 
Amidst all the chronic inflammation, there are suggestions of the existence of a 
repair phenomenon as evidenced by the formation of fully-differentiated 
interneurones in chronically demyelinated plaques and shadow-plaques (areas 
of remyelination), which are a consistent feature in the early stages of MS 80. 
Remyelination within active plaques appears to be accomplished by 
oligodendrocyte progenitor cells recruited to sites of demyelination. The 
presence of clinically silent MRI lesions paints a picture of a silent conflict 
between pathological processes and repair or adaptation (plasticity). Moreover, 
a comparison of MRI with histophathological findings found signs of 
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remyelination in 42% of areas investigated, confirming that remyelination is a 
frequent occurrence in MS 81. Previously held belief that repair is scarce in the 
adult CNS may have misled us to believe that it is absent altogether.  
 
In the later stages of the disease atrophy appears to be the predominant feature 
and neuroplasticity the exception, not the rule. Remyelination, whilst rapid and 
extensive in new plaques and in the gray matter, evidence from chronic plaques 
suggest that remyelination may be less conspicuous here and mostly restricted 
to plaque edges 82; 83. Halting the inflammatory response leading to relapses in 
mouse model of MS (chronic relapsing EAE) does not prevent disease 
progression based on deterioration in mobility and the development of spasticity 
84. Similarly evidence from Campath-1H, a humanised monoclonal antibody that 
causes prolonged T lymphocyte depletion, suggests that halting lymphoid cell 
inflammation does not appear to curb the accumulation of disability in 
secondary progressive MS patients 85. The continuation of axonal loss in non-
relapsing progressive MS is poorly understood. It has been suggested that 
inflammation in early disease primes the damaged axons for degeneration in 
the future 85, and also it is likely that persistent demyelination 86 and loss of 
homeostasis of ionic gradients in axons 87 are other necessary mechanisms 
leading to axonal loss. In EAE, damage to the corticospinal tract (CST) is a 
predictor of clinical paralysis, with almost two-thirds of axons displaying 
substantial degeneration 88. CST cells are noted for their lack of regenerative 
capacity 89 and may explain some of the limited recovery observed after injury 
or axotomy.  
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The MS model can therefore be used to study the molecular and cellular 
mechanisms that contribute to neuro-restoration or lack thereof. There is a 
plethora of knowledge on axonal loss and neurodegeneration, but little is known 
about the mechanisms sustaining neuroplasticity and the consequences of 
chronic damage. 
 
1.3 Biomarkers 
 
Depending on the subject area the word ‘biomarker’ has a specific meaning as 
well as application, which has understandably lead to some confusion on the 
subject. The official National Institute of Health (NIH) definition of a biomarker in 
biological sciences is: ‘a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacological responses to a therapeutic intervention’ 90; 91. A biomarker is 
different from that of a ‘clinical endpoint’ which applies primarily to an outcome 
in a therapeutic intervention trial that provides the most compelling evidence in 
support of a therapeutic effect or lack of, an example of this is mortality 90; 92. 
Biomarkers are also mistakenly referred to as ‘surrogate endpoints’ which are 
measures that can be used in substitution of a clinically meaningful endpoint 93. 
A surrogate marker requires a long list of characteristics to be established, 
including technical validation, biological feasibility, be translational across 
species, and not least to correlate with other measures of a similar nature, such 
as MRI or neurophysiology, to mention an important few. Consequently, it 
comes as no surprise that only a subset of biomarkers ever reach the status of 
surrogate endpoints and remain as only “candidate” surrogate markers 94. 
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Due to the complex nature of nerve regeneration it is unlikely that a single 
biomarker will be representative of the whole process. The majority of 
biomarkers are from secondary biological processes and their relationship to 
the primary pathological event is not directly causal but due to bystander or 
associated effects 94. Therefore in order to exemplify what takes place during 
nerve regeneration a multifactorial all-inclusive approach to selecting 
biomarkers is needed comprising of markers that are both disease-specific and 
process-specific, but also to be practically useful they should not be remote 
from the clinical endpoint. Moreover, they should compare favourably with other 
well-established clinical and laboratory parameters already in use. This will 
require the translation of biomarkers from in-vitro experiments and animal 
models, into well-controlled clinical trials (Figure 1-4). Occasionally as in 
regenerative work, the biomarkers may be so novel that there may be no 
relevant comparisons, in which case they will require qualification at a later 
stage. 
 
In neuroprotection studies, one of the major hurdles to success has been 
insufficient appreciation of the complexities of the human central nervous 
system. It therefore stands to reason that, a better understanding of nerve 
regeneration and repair will go a long way to help researchers develop and test 
neuroprotective strategies where, biomarkers may have a key role to play. So 
far in neuroscience, imaging in particular MRI has established a precedent in 
diagnosing and monitoring disease process 95. However, MRI is unable to 
image directly remyelination and neurogenesis. Magnetization transfer ratio 
(MTR) has been shown to be a reliable marker of myelin content in 
demyelinated  lesions  and  normal  appearing  white  matter (NAWM) based on 
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DISEASE ISOFORMS CONC. SAMPLE TECHNIQUE REFERENCES 
Neural Cell Adhesion Molecule (NCAM) 
Alzheimer’s 
disease 
Total 
NCAM 
↑/↔ CSF ELISA 97; 98 
 Total 
NCAM 
↑ Plasma ELISA 97 
 100-130 
kDa (low), 
>130 kDa 
(high) 
↑ Serum Western 
blotting 
99 
Multiple 
Sclerosis 
Total 
NCAM 
↓/↔ CSF ELISA 98; 100; 101 
 
Schizophrenia Total 
NCAM  
↑ CSF Western 
blotting 
102; 103 
 120 kDa ↑ CSF  Western 
blotting 
104 
 105-115 
kDa 
cleaved 
NCAM  
↑ /↓ in 
FE-NN* 
CSF Western 
blotting 
105; 106 
 165 kDa 
(heavy), 
155 kDa 
(medium) 
VASE 
↑ CSF Western 
blotting 
107 
 140 kDa 
(low) VASE 
↔ CSF Western 
blotting 
107 
Bipolar 
disorder 
(BPD) 
165 kDa 
(heavy), 
155 kDa 
(medium), 
140 kDa 
(low) VASE 
↔ CSF Western 
blotting 
107 
 120 kDa ↑ in 
BPD 
type I 
not II 
CSF Western 
blotting 
108 
Growth Associated Protein (GAP)-43 
Alzheimer’s 
disease 
N/A ↑/↔ CSF ELISA 109; 110 
Parkinson’s 
disease 
N/A ↓ CSF ELISA 110 
Multiple 
Sclerosis 
N/A ↔ CSF ELISA 111 
 
Table 1-1 Levels of soluble NCAM and GAP-43 observed in blood and CSF of 
neurological disorders. 
* First-episode neuroleptic-naïve patients. 
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Figure 1-4 A flow chart of fit-for-purpose validation of biomarkers for application in 
clinical trials. Incorporation of biomarkers into clinical trials as predictive indices of patient 
response entails biomarkers demonstrating their efficacy in preclinical and early and late phase 
trials or equivalent. 
 
histopathological correlations, but can be confounded by the effects of 
inflammation 96. By comparison molecular research into the CNS has been vast, 
with a large body of work primarily devoted to that of disease pathophysiology. 
Studies focused on neuroregeneration and plasticity, however, have been few 
in number as well as conflicting in their messages 112; 113; 114, making it difficult to 
draw tangible conclusions. Much of the research into nervous system 
regeneration and repair relies heavily on knowledge from non-human animal 
studies. Information from the human CNS at different stages of development 
and injury are rare due to scarcity of post-mortem material. Therefore, for 
biomarker studies in living subjects, body fluids such as serum, plasma, urine 
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and CSF are a more suitable choice 91. Urine sampling is non-invasive but 
susceptible to urinary tract infections which can induce certain biomarkers 
leading to supranormal values 115, and collection volumes may vary depending 
on the degree of bladder dysfunction 116. Analysing biomarkers in blood is an 
alternative and although moderately invasive is relatively easy to collect. 
However, the existence of an active clotting system complicates analysis and 
the high protein content may interfere with tests in even so called “optimised” 
ELISA kits designed to minimize interference 117. Conversely, the protein 
concentration of the CSF is much lower owing to the size restriction posed by 
the blood-brain-barrier, and the absence of a clotting system makes this the 
ideal biofluid for biomarker analysis. The CSF is also an accessible liquid 
extension of the CNS and a better reflection of the processes taking place 
within 118. In addition, some proteins are present in very low concentrations in 
the blood but their relative concentration is far more significant in the CSF as 
they are exclusively synthesised in astrocytes or in neurones – for example 
Beta-2-transferrin which generally used in the determination of the aetiology of 
nasal discharge to represent CSF leak 119. As a last remark, the procedure of 
obtaining CSF is invasive requiring considerable expertise and the total volume 
of CSF is far lower than the total volume of blood (150-270 ml of CSF 120 
compared to 5 l of blood in humans), limiting the amount that can be sampled 
for analysis at any one time. 
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1.4 Hypothesis and aims 
 
The goal of this study was to investigate and validate potential biomarkers of 
neuro-restoration, specifically those involved in neuronal pathfinding, which can 
be used to measure plasticity in the adult CNS following injury, and to discuss 
emerging ideas regarding how these molecules are regulated in disease. My 
hypothesis is that the nervous system has an intrinsic capacity or potential for 
regeneration, but this capability may be dramatically reduced by disease. 
 
NCAM and GAP-43 were selected as candidate biomarkers for further study 
based on existing supportive evidence for their role as surrogate markers of 
neuroplasticity, as they are predominantly expressed in the brain and may be 
preferentially released after neuronal damage, and their protein sequences are 
conserved across different species considered necessary for the translation of 
biomarkers from animal to human models (see Table 1-2). 
 
The specific aims of the thesis are detailed below: 
 
1) To develop sensitive enzyme-linked immunosorbent assays (ELISA) 
to quantify levels of NCAM and GAP-43 in cerebrospinal fluid. 
 
2) To generate recombinant GAP-43 suitable for use in ELISA. 
 
3) Characterise the soluble isoforms of NCAM in CSF using mass 
spectrometry. 
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4) Using in-vitro and in vivo models of MS track the expression of NCAM 
through the disease state in order to understand the effects of disease 
progression on neuronal plasticity. 
 
5) Compare the levels of CSF NCAM and GAP-43 in control subjects and 
in patients suffering from MS and other neurological disorders, and to 
correlate this with patient outcome measures. 
 
6) Establish guidelines for biomarker validation and reporting. 
 
 
Table 1-2 Sequence alignment scores for human NCAM and GAP-43 by species 
(generated using NCBI Blastp suite). Percentage sequence homology with other species is 
given; this has practical issues for biomarker experiments in animal models and translating this 
work across to humans. 
 
 
 
 
 
Accession Entry name Protein 
name 
Length & 
mass 
Species Identity 
P13591 NCAM1 
HUMAN 
Neural cell 
adhesion 
molecule 1 
(NCAM-1) 
858 aa, 
94,574 Da 
Rhesus 
macaque 
99% 
Rat 
 
95% 
Mouse 
 
93% 
P17677 NEUM 
HUMAN 
Growth 
associated 
protein 43  
(GAP-43) 
238 aa, 
24,803 Da 
Rhesus 
macaque 
98% 
Rat 
 
73% 
Mouse 76% 
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2 NEURAL CELL ADHESION MOLECULE (NCAM):  
A novel method for analyzing NCAM isoforms using 
mass spectrometry combined with protein retrieval and 
the development of a sensitive quantitative ELISA for 
NCAM 
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2.1 Introduction 
 
The neural cell adhesion molecule (NCAM) constructed from domains of the 
immunoglobulin superfamily plays an integral role in neuronal repair and 
regeneration and has been implicated in such diverse processes as neuronal 
cell-cell/cell-substratum adhesion, axonal outgrowth, guidance and 
fasciculation, myelination, synaptic plasticity and myogenesis (see reviews by 
51; 121; 122; 123; 124). NCAM was originally described by Jorgensen and Bock as 
“D2” protein 125. It is transcribed from a single gene on chromosome 11, but 
because of alternative splicing of the protein it exists in many isoforms 126; 127. 
The three major isoforms are NCAM-120, NCAM-140 and NCAM-180, 
corresponding to their respective molecular weights when separated by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). They differ 
primarily in their C-termini with NCAM-180 having the longest intracellular 
component, whereas NCAM-120 is linked to the plasma membrane via a 
glycosyl-phospatidylinositol (GPI) anchor with no intracellular component 
(Figure 2-1). The N-termini of all three isoforms is identical, comprising of five 
Ig-like domains and two fibronectin type III repeats. The expression of NCAM 
isoforms takes place in a tissue (NCAM-120 is found in glia, NCAM-140 in 
neurons and glia, and NCAM-180 in neurons) and developmental stage specific 
manner 128; 129, although their individual contributions to the overall plasticity-
promoting role of the protein is less well understood. 
 
Occasionally, NCAM polypeptides with differing sizes from the major isoforms 
have been described 130; 131; 132. These contain minor variations in the length of 
the extracellular domain of NCAM, and it is possible that a single band 
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observed by immunoblotting may therefore contain many different isoforms. In 
pathology, a selective increase in 105-115kDa NCAM and VASE (variable 
alternative spliced exon), a 10 amino acid insert into the fourth NCAM domain, 
have been described in patients with schizophrenia 107; 133; 134. In bipolar mood 
disorder patients a preferential rise in the 120kDa NCAM and 140kDa VASE 
isoform has been found 108; 135. Altered or over-expression of NCAM isoforms 
has been observed in a variety of tumours, including gliomas, breast, colon, 
small cell lung carcinoma, and melanoma 136; 137; 138; 139; 140; 141.  
 
Figure 2-1 Schematic diagram of three main classes of NCAM. They vary only in their 
cytoplasmic domain: NCAM-120 kDa (GPI anchored), NCAM-140 kDa (short cytoplasmic 
domain), NCAM-180 kDa (long cytoplasmic domain). While the extracellular domain consists of 
five immunoglobulin (IgG)-like domains followed by two fibronectin type-III domains. 
 
In addition to membrane-bound isoforms of NCAM soluble versions of all three 
major isoforms exist in the blood, CSF, amniotic fluid and cell culture 
supernatants 131; 142; 143; 144. They are thought to arise from spontaneous release 
from the membrane following extracellular cleavage by phosphatidylinositol-
specific phospholipase C (PI-PLC), as in the case of NCAM-120, or possibly by 
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the degradation of the extracellular matrix in the transmembrane isoforms or 
active secretiion 142; 145. Biologically, their role is somewhat mysterious, with one 
description of them being regulatory molecules by interfering with NCAM-
mediated cell adhesion or modulating other extracellular matrix components by 
binding to them 142, or simply waste products of the nervous system.  
 
Serum levels of NCAM are higher than in the CSF, although in paired samples 
there appears to be no correlation between the two 146. Recently, Massaro et al. 
reported that CSF NCAM is also unsialylated, whilst the sera are PSA 
(polysialic acid) – positive, further highlighting differences between the two 
compartments 147. Despite the extent to which NCAM has been explored in the 
research field we have yet to find an analytical use for it. In MS, whilst reduced 
levels have been noted in non-acute MS,  following an acute exacerbation 
NCAM levels rose steadily in the CSF in patients treated with steroids, 
suggesting possible involvement in nervous system recovery after an 
inflammatory insult 148. 
 
2.2 Aims 
 
The aims of the work presented in this chapter were firstly to study the 
distribution of NCAM isoforms in blood and CSF space to determine whether 
they were comparable, and then to determine which isoforms were present in 
the CSF.  
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Secondly, to determine whether NCAM quantification in CSF could serve as an 
indicator (biomarker) of plasticity and repair in neurological disorders. 
 
2.2.1 The detection of NCAM isoforms: past and future 
 
Previously NCAM isoforms have been inferred indirectly from NCAM protein 
isoform sizes determined by western blotting techniques. The serum matrix is 
complex, requiring sample dilution and loss of sensitivity whilst dealing with low 
abundant proteins. One way of overcoming these limitations is to combine 
immunoaffinity protein capture with mass spectrometric methods of detection, 
which provides targeted assessment of isoforms present in biological fluids, and 
also permit their characterization through peptide sequencing.  
 
Using a monoclonal antibody specific for the N-terminal portion of NCAM which 
is able to identify the common molecular forms (-120, -140, -180kDa isoforms) 
as well as any additional variations in the extracellular isoforms of NCAM, I 
have developed a SELDI-based expression profiling method for studying the 
NCAM isoforms in matched serum and CSF samples. Bound NCAM was eluted 
directly without intervening fractionation steps and analysed using ESI 
(electrospray ionization)-Q-TOF (tandem quadrupole/orthogonal-acceleration 
time-of-flight) sequencer.  
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2.2.2 Quantitative NCAM analysis  
 
An ELISA allows rapid quantitation of a large number of samples for the 
presence of an analyte, allowing high throughput quantitation. The resulting 
quantitative signal is dependent on the sensitivity and specificity of the assay, 
which is largely antibody dependent, but is also determined by the ELISA format 
(direct vs. indirect). Several groups, including our own have previously 
attempted to produce NCAM ELISAs but a few simple or robust assays exist 
owing to difficulties in obtaining reagents, since antibodies are often produced 
in-house, or that only look at a specified form of NCAM, for example PSA-
NCAM. Using a monoclonal NCAM antibody specific for an epitope on the N-
terminus of NCAM, an ELISA that could potentially summate signals from all 
NCAM isoforms was developed, thereby providing a quantitative signature of 
neuronal plasticity. The levels of total NCAM in the CSF of different neurological 
conditions were subsequently determined. 
 
2.3 Materials and methods 
2.3.1 Patients 
2.3.1.1 Mass spectrometry and western blot patient material 
 
Paired CSF and serum samples were from secondary progressive MS patients 
within the placebo arm of the Lamotrigine trial (NCT00257855) 149. The study 
was approved by the Joint University College London and University College 
London Hospitals Committee on the Ethics of Human Research. All participants 
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gave informed consent for blood and lumbar puncture procedures. Clinical 
diagnosis of MS was supported by the presence of intrathecal oligoclonal band 
patterns on gel electrophoresis and an intercurrent infection was excluded 
bacteriologically. Samples were frozen and kept at -70oC until analysis. 
 
2.3.1.2 CSF samples for NCAM ELISA 
 
CSF samples used in this part of the study were obtained from the CSF 
laboratory, National Hospital for Neurology and Neurosurgery, Queen Square, 
U.K. There was local research ethics committee approval for use of these 
samples in the development of new investigations. CSF samples had been 
centrifuged at receipt and stored at -20oC. 
 
NCAM analysis was performed blind to clinical data. The final clinical diagnoses 
on the samples were obtained from clinical notes retrospectively; those in whom 
the diagnosis was unclear were not included in the final analysis. CSF NCAM 
was measured in a total of 225 samples. Their underlying diagnoses were 
benign-intracranial hypertension (BIH), multiple sclerosis (MS), neuropathy, 
Alzheimer’s disease (AD), cognitive impairment (CI), motorneurone disease 
(MND), meningitis and viral encephalitis. The control population consisted of 
headache and back pain with normal imaging and CSF profile. Their 
characteristics is summarised in Table 2-1. 
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Table 2-1 Clinical characteristics of patients used to measure CSF NCAM (N=225). 
  
Diagnosis N Gender 
(M:F) 
Age 
(years) 
BIH 
MS 
Neuropathy 
AD 
CI 
MND 
Meningitis 
Viral encephalitis 
Controls 
36 
51 
27 
37 
12 
15 
13 
17 
17 
4:32 
15:36 
13:14 
19:18 
7:5 
8:7 
6:7 
13:4 
9:8 
31 (18-51) 
44 (17-74) 
50 (23-75) 
60 (47-74) 
61 (51-78) 
60 (37-81) 
46 (21-62) 
54 (22-79) 
61 (31-81) 
All age values are expressed as means (range). N = number of individuals; M = male; F = 
female; BIH = Benign Intracranial Hypertension; MS = Multiple Sclerosis; AD = Alzheimer’s 
Disease; CI = Cognitive Impairment; MND = Motor Neurone Disease. 
2.4 Buffers and Solutions 
 
Buffers and solutions used in this Chapter are given in the Appendix to Chapter 
2. 
 
2.5 Methods 
2.5.1 Overview 
 
An overview of the methods used for NCAM isoform analysis and total NCAM 
level quantification is given in Figure 2-2. 
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Figure 2-2 An outline of NCAM mass spectrometry and quantification experiments. 
Serum/CSSF NCAM SELDI-TOF MS analysis: to characterise NCAM found in the CSF versus 
sera using anti-NCAM antibody bound to RS100 array using SELDI-TOF-MS which permits on-
spot segregation of native NCAM from other protein populations in the samples. NCAM 
identification using ESI Q-TOF MS analysis: a technique of dissociating NCAM from the array 
was developed in order to permit direct ESI Q-TOF peptide analysis. NCAM in neurological 
disorders: the development and validation of a new NCAM ELISA for protein quantification, 
including exploratory study of endogenous anti-NCAM antibodies which may have the potential 
to intefere with the analysis and quantification of NCAM in neurological disorders.  
 
2.5.2 Sample preparation 
 
Blood samples were collected in 10mL sterile collection tubes (BD vacutainer®, 
#367820) containing no anticoagulant and allowed to clot spontaneously over a 
period of 10-15mins. Serum was then collected after centrifugation at 2,000 g x 
10min at room temperature, and stored in aliquots until analysis. 
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All CSF samples were collected in sterile polypropylene tubes as they exhibited 
low peptide binding. They were then centrifuged at 750 g x 5min at room 
temperature. The cell-free supernatants were aliquoted and stored until 
analysis. Only CSF samples without macroscopic blood contamination were 
included in the analysis. 
 
2.5.3 Antibodies 
 
Anti-NCAM mouse monoclonal antibody (BD Biosciences, #559043) used as a 
capture antibody in the ELISA and for immunoaffinity capture in SELDI 
experiments recognises the third extracellular immunoglobulin-like domain at 
the amino-terminus that is shared by NCAM-120, -140, and -180. The rabbit 
polyclonal anti-NCAM antibody (Chemicon, #AB5032) raised against purified 
chicken NCAM was used as the detector antibody in the ELISA. Whilst, HRP-
coupled goat anti-rabbit IgG (DAKO, #P0217) was used as the reporter 
antibody.  
 
Rabbit polyclonal anti-NCAM antibody (Chemicon, #AB5032) was used as the 
detector antibody in the positive control and omitted for the negative control in 
the anti-NCAM antibody immunoblot. Polyclonal swine anti-rabbit IgG 
conjugated with HRP (Dako, #P0217) and Polyclonal rabbit anti-human IgG 
conjugated with HRP (Dako, #P0214) were used as reporter antibodies.  
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2.5.4 Western blot analysis of NCAM in CSF 
 
CSF samples were prepared by mixing 19.5 μl of CSF, 7.5 μl LDS sample 
buffer (Invitrogen) and reducing agent, 3 μl 0.5 M dithiothreitol (DTT or Clelands 
reagent, Sigma) and boiling for 15 min. Samples were electrophoresed on a 
NuPage 4-12% Bis-Tris 10 well 1.0 mm precast gel (Invitrogen) at 200 V, 120 
mA and 25 W for 35 minutes in 2-{N-Morpholino]ethanesulphonic acid (MES) 
running buffer (Invitrogen) in a buffer tank and power pack (Invitrogen). The gel 
was then electroblotted to nitrocellulose (BioRad) using a semi-dry 
electroblotting system (Novex®, Invitrogen) in transfer buffer (Invitrogen) plus 
10% methanol (VWR) for transfer of one gel (20% methanol when transferring 
two gels) for two hours at 25 V, 160 mA and 17 W. Non-specific binding was 
blocked using 2% w/v semi-skimmed milk (Marvel, Premier Brands Ltd.) in 0.9% 
saline for at least 1 h on a slow rocker and rinsed off with two changes of saline. 
The blot was then incubated overnight at 4oC in primary antibody; anti-NCAM 
mouse monoclonal antibody diluted 1:500 in 0.2% w/v milk. After washing with 
0.2% semi-skimmed milk in 0.9% saline containing 0.05% Tween 20 five times 
at 5 min intervals, the blot was incubated in the second antibody; swine anti-
rabbit-HRP diluted 1/200 in 0.2% w/v milk for 2 hours. The washing step was 
repeated and the HRP activity detected using enhanced chemiluminescence 
(ECL). 5 ml of SuperSignal West Pico Luminol enhancer solution and 
SuperSignal West Pico stable peroxide solution (Thermo Scientific) were 
mixed together prior to immersing the membrane in this for approximately three 
minutes with agitation and then transferred to FluroChem SP 
chemiluminescence system (Alpha Innotech) for imaging exposure and 
interpreted on the accompanying AlphaEase v4.0 Image Analysis software.  
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2.5.5 Western blot analysis of endogenous antibodies against 
NCAM in serum/CSF 
 
A random selection of serum/CSF samples from MS subjects were tested for 
reactivity with recombinant NCAM by western immunoblotting looking for 
endogenous antibodies to NCAM potentially leading to antibody-associated 
interference in ELISA. MS subjects were selected as the elevated humoural 
response present in this disorder makes it more likely that some of these are 
formed against NCAM. 
 
In brief, 50 μg of protein (R&D Systems, #2408-NC) was solubilised in LDS 
sample buffer (Invitrogen) and reducing agent DTT (Sigma), boiled for 10 min 
as described earlier and separated on NuPage 4-12% Bis-Tris 2D well precast 
gel (Invitrogen). The gel was then electroblotted onto nitrocellulose membrane 
(BioRad) using the Novex® semi-dry transfer system (Invitrogen). The 
membrane was blocked for 1 h at room temperature in 2% w/v semi-skimmed 
milk (Marvel) in 0.9% saline. Afterwards, the membrane was placed in an 
incubation manifold (Amersham Pharmacia) which allowed different samples to 
be tested against the same separated protein. The rabbit polyclonal anti-NCAM 
was used as a positive control diluted 1:500 in 2% w/v semi-skimmed milk in 
saline (saline was used as the negative control), and MS sera and CSF were 
diluted 1:500 dilution or neat, respectively. Each chamber contained 0.5 ml of 
sample. The entire manifold was placed on a rocker so that the sample followed 
back and forth from one end of the chamber to the other and left overnight at 
+4oC. Afterwards the samples were discarded and the nitrocellulose was 
washed with 0.2% semi-skimmed milk in saline containing 0.05% Tween 
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(Sigma) 10 times at 10 min intervals between washes to remove unbound 
antibody. Anti-rabbit IgG/HRP for the positive control and anti-human IgG/HRP 
for the MS samples at 1 in 1000 dilution, were added and incubated with gentle 
rocking for 2 h at room temperature. The nitrocellulose was washed as 
previously described and removed from the manifold. Identification of antibody 
reactivity was carried out using ECL. 
 
2.5.6 Surface-enhanced laser desorption/ionization mass 
spectrometry (SELDI-TOF MS) and protein retrieval 
 
Immunoaffinity capture of NCAM from MS CSF and sera were performed using 
the eight-spot format RS100 ProteinChip arrays (BioRad).  
 
Monoclonal anti-NCAM antibody (BD Biosciences, #559043) containing 1.0 
mg/ml of protein in PBS (phosphate buffered saline, Sigma) was coupled to a 
single spot on the array (x8) and incubated overnight at 4oC in a humidity 
chamber. Following this, the residual sites were blocked using 0.1% BSA/PBS 
and incubated for 30min at room temperature. Unbound antibodies were 
removed by washing once with 0.1% (v/v) Triton-X (Sigma) PBS wash buffer on 
an agitator, and twice in PBS (containing no Triton) for 15min each. The arrays 
were then placed in parallel in a 96-well format Bioprocessor (Ciphergen 
Biosystems, Fremont, CA, U.S.A.) and 30μl of paired crude CSF/serum was 
added to each spot alternatively with the last two containing recombinant NCAM 
(R&D Systems, #2408-NC) and PBS/BSA only as positive and negative 
controls, respectively. Using the Bioprocessor maximised antibody exposure to 
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NCAM in the sample. The Bioprocessor was then placed in a humidity chamber 
at 4oC and incubated overnight with gentle agitation to again facilitate antibody-
antigen capture. After incubation, the sample was removed from each array and 
washed twice for 15min in wash buffer and once in PBS for 15min on the 
agitator. Lastly, to remove the salts, the arrays were rinsed thrice in 5mM 
ammonium acetate, pH7 for 10s each. The arrays were then air-dried at room 
temperature. Prior to SELDI-TOF MS analysis, 2 x 1μl saturated sinapinic acid 
(SPA) matrix in 50% acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA) was 
applied to one of the spots as well as the control spot and air-dried.  
 
Mass analysis was performed using the SELDI-TOF ProteinChip System with 
integrated ProteinChip software (Ciphergen Biosystems, Fremont, CA, U.S.A.) 
collecting the data. Each array was read at high mass with laser intensity set at 
288 U, detector sensitivity of 9 and the focus mass optimized from 120-180kDa. 
Retrieval of antibody-bound protein was carried out on the CSF spots without 
the addition of SPA. Using an up-and-down motion each CSF spot was rinsed 
with 3 μl of 70% ACN and 0.2% TFA, followed by 3μL of 50% formic acid: 25% 
ACN: 15% isopropanol: 10% water. Eluate was transferred to an Eppendorf 
tube and freeze-dried. 
 
2.5.7 ESI Q-TOF MS analysis 
 
This portion of the analysis was performed by Dr Wendy Heywood, Proteomics 
department, Institute of Child Health, London, U.K.  
 
 
 
51 
 
20 μl of 100mM Tris, pH 7.8 containing 6M urea was added to the freeze dried 
sample protein and left to shake at room temperature for 1hr. Deglycosylation 
was performed using PNGase F (#P7367, Sigma) to increase protein coverage 
since NCAM has a lot of glycans that can hinder trypsin digestion and mass 
spectrometry detection. Disulphide bridges were reduced by the addition of 3μl 
of 100mM Tris-HCL, pH 7.8 containing 5M DTE and incubation at room 
temperature for 60min. Free thiol groups were carboamidomethylated followed 
by incubation with 6μL of 100mM Tris-HCL, pH 7.8 containing 5M 
iodoacetamide. The solution was then diluted with 155 μl H2O, vortexed and 2 
μg of sequence grade trypsin was added to the solution. Samples were 
incubated overnight at 37oC in a water bath. Proteins were identified by direct 
analysis of the reaction mixture described above. All analyses were performed 
using a nanoAcuity HPLC and QTOF Premier mass spectrometer (Waters 
Corporation, Manchester, U.K.). Peptides were trapped and desalted prior to 
reverse phase separation using a Symmetry C18 5μm, 5mm x 300μm pre-
column. Peptides were then separated prior to mass spectral analysis using a 
15cm x 75 μm C18 reverse phase analytical column. Peptides were loaded onto 
the pre-column at a flow rate of 4 μl/min in 0.1% formic acid for a total of 4 mins. 
They were eluted off the pre-column and separated on the analytical column 
using a gradient of 3-40% acetonitrile [0.1% formic acid] over a period of 120 
min and at a flow rate of 250 nl/min. The column was washed and re-generated 
at 300 nl/min for 10 min using a 99% acetonitrile [0.1% formic acid] rinse. After 
all non-polar and non-peptide material were removed, the column was re-
equilibrated at the initial starting conditions for 20 min. Column temperature was 
maintained at 35oC. Mass accuracy was maintained during the run using a lock 
spray of the peptide [glu1]-fibrinopeptide B delivered through the auxiliary pump 
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of the nanoAquity at a concentration of 300 fmol/l and at a flow rate of 300 
nl/min.  
 
Peptides were analysed in positive ion mode using a Q-Tof Premier mass 
spectrometer (Waters Corporation, Manchester, U.K.) and was operated in v-
mode with a typical resolving power of 10,000 FWHM. Prior to analyses, the 
TOF analyser was calibrated using [glu1]-fibrinopeptide B (785.8426 m/z) with a 
sampling frequency of 30 sec. Accurate mass LC-MS data were collected in a 
data independent and alternating, low and high collision energy mode. Each 
low/high acquisition was 1.5 sec with 0.1 sec interscan delay. Low energy data 
collections were performed at constant collision energy of 4 V, high collision 
energy acquisitions were performed using a 15-40 V ramp over a 1.5 sec time 
period and a complete low/high energy acquisition achieved every 3.2 sec. 
 
ProteinLynx GlobalServer version 2.3 was used to process all data acquired. 
Protein identifications were obtained by searching UniProt/Swiss-Prot. Protein 
identification form the low/high collision spectra for each sample was processed 
using a hierarchical approach where more than three fragment ions per peptide, 
seven fragment ions per protein and more than two peptides per protein had to 
be matched.  
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2.5.8 Establishment of a two-site sandwich ELISA for quantification 
of NCAM 
 
2.5.8.1 The two-site ELISA 
 
I specifically choose the two-site ELISA design as binding of the protein by two 
different antibodies has the obvious advantage of increasing the specificity of 
the assay. The format was a monoclonal-polyclonal sandwich assay using a 
single epitope specific monoclonal antibody as the capture antibody and a 
polyclonal detector antibody which recognises other epitopes of the protein. A 
third enzyme labeled antibody was used to generate colour which could be 
measured by an optical reader (Figure 2-3).  
 
2.5.8.2 Calibration 
 
The assay was calibrated using recombinant human NCAM (R&D Systems, 
#2408-NC). The vial was reconstituted in 0.1% BSA/1M PBS, pH 7.4 and 
subsequently diluted to give a standard curve ranging from 500 ng/ml to 0 ng/ml 
in a solution of 5% semi-skimmed milk/1M PBS, pH 7.4 as diluent. 
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Figure 2-3 Schematic representation of the two-site ELISA. A 96-well microtitre plate was 
coated with the capture antibody. Samples are then added to the wells and any antigen present 
bind to the antibody. A detection antibody is added, followed by an enzyme-labeled 
antibody.TMB substrate is added as a final step and is converted by the enzyme into a 
detectable form. 
 
2.5.8.3 Assay protocol 
 
96-well microtitre plates (Nunc MaxiSorp, Nunc, Roskilde, Denmark) were 
coated overnight at 4oC with 100 μl 2.5 μg/ml of mouse monoclonal anti-NCAM 
(capture antibody) in 1M PBS, pH 7.4 (Sigma). The wells were then washed 
once with 0.05% Tween-20/1M PBS solution (0.05% Tween/PBS), and 
subsequently blocked at room temperature for 1 h with 5% semi-skimmed milk 
in PBS (5% milk/PBS) solution. The wells were then rinsed once with 0.05% 
Tween/PBS leaving the plate to stand for 5 min before decanting. Aliquots of 25 
μl of standards, controls and CSF samples and 75 μl of 5% PBS/milk solution 
were added to the plate wells in duplicate and incubated overnight at 4oC with 
shaking. Wash step was repeated five times leaving to stand for 5 min per 
wash, and incubated for 1 h 30 min with 100 μl polyclonal rabbit anti-NCAM 
(detector antibody) at 1/1000 dilution with shaking. Again after washing 100 μl 
conjugated HRP goat anti-rabbit (reporter antibody) at 1/1000 dilution were 
added to each well and incubated at room temperature for 1 h worth of shaking. 
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Lastly, after a final wash step 100 μl of TMB (Supersensitive 3,3’,5,5’ 
tetramethylbenzidine, Sigma) was added and the colour development allowed 
to develop and then stopped using 50 μl 1M HCL (Sigma). Absorbencies were 
determined photometrically at 450 nm (test) and 700 nm (blank) using an ELISA 
plate reader (FLUOstar Omega, BMG Labtech) and the concentrations of 
NCAM interpolated using the standard curve generated. 
 
2.5.8.4 CSF albumin quotient and blood-brain barrier dysfunction 
 
The albumin quotient [1] and IgG index [2], indicators of blood-brain barrier 
permeability and intrathecal IgG production, respectively, were calculated. 
Albumin concentrations in serum (g/l) and CSF (mg/l) and similarly, IgG were 
quantified by nephelometry (BN ProSpec, Siemens).  
 
     ALBCSF          [1] 
     ALBSERUM 
 
    IgGCSF    ALBSERUM  [2] 
    IgGSERUM     ALBCSF 
 
Spearman-rank correlations were calculated to assess if there was relationship 
between albumin quotients, IgG index and NCAM levels. 
 
 
x 100 
x 
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2.5.8.5 Statistical analysis 
 
All analysis was performed using SPSS version 16. Comparisons between the 
different diagnostic categories were performed using ANOVA after establishing 
normality using the one-sample Kolmogrov-Smirnov test. The level of statistical 
significance was set at 0.05. Multiple comparisons were adjusted using 
Bonferroni correction. Further sub-group analyses were performed in the MS 
and neuropathy categories. The effects of age and gender on NCAM values 
were tested using regression analysis with age as a covariate and gender as a 
factor. Spearman-rank correlation was performed between CSF NCAM, albumin 
quotient and IgG index to assess whether NCAM values rose with blood-brain 
barrier dysfunction or intrathecal IgG synthesis. 
 
2.6 Results 
 
2.6.1 Optimisation of antibody capture in SELDI-TOF MS 
 
Optimisation steps are typically required to evaluate antibody-antigen 
interactions, but I found using CSF specimens particularly difficult since they 
were more likely to be negative or yield low intensity peaks at the final analysis 
(Figure 2-4). A similar problem was not encountered when using serum 
samples. This may be a reflection of the lower concentrations of protein 
normally found in cerebrospinal fluid. I therefore inserted the arrays into an 
eight-well Bioprocessor (Ciphergen Biosystems) for sample incubation, using 
which much larger volumes of CSF could be loaded, akin to a 96 ELISA well 
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plate. Samples were then incubated overnight at 4oC to allow additional binding. 
This produced better peak definition with CSF samples than previously (Figure 
2-5). 
 
 
 
Figure 2-4 SELDI peaks in CSF (top) and serum (bottom) prior to optimisation. This 
generated small m/z peaks corresponding to molecular weights in the CSF; the same problem 
was not encountered with serum samples. 
 
 
 
Figure 2-5 SELDI peaks in CSF (top) and serum (bottom) after optimisation. This 
generated m/z peaks with better definition in the CSF samples. The peak at about 75 kDa in the 
CSF and 54 kDa in the serum are the double-charged proteins. 
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2.6.2 Identification of soluble NCAM by SELDI-TOF MS reveals 
differences and similarities between MS patient sera and CSF 
 
Protein profiling experiments by antibody pull down and SELDI MS revealed 
distinct cluster of peaks at mass to charge ratio (m/z) of approximately 75 kDa, 
91 kDa, 127 kDa, and 150 kDa in MS CSF. Figure 2-6 shows representative 
profiles from five MS patients showing matching signatures suggesting identical 
protein compositions. Control run using recombinant NCAM (molecular weight 
120 kDa, under reducing conditions) produced peaks at m/z approximately 46 
kDa, 92 kDa, 150 kDa and 184 kDa, and the negative control identified a peak 
at m/z of approximately 67 kDa corresponding to albumin which used as the 
blocking agent. Paired serum analysis demonstrated shared peaks at m/z of 
approximately 75 kDa, 91 kDa, and 150 kDa similar to the CSF but also a 
distinctly large peak at m/z of approximately 54 kDa which has been highlighted 
as the doubly ionized form of the original protein fragment at 108 kDa, i.e. same 
mass but twice the charge. The intensities of the shared peaks were 
comparable between the two compartments. The protein composition was 
elucidated using shotgun sequencing which confirmed the presence of NCAM in 
both the CSF and serum samples, as well as few other proteins including the 
mouse antibody (see Table 2-2). 
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Table 2-2 Shotgun sequencing results from SELDI MS analysis of paired MS sera and 
CSF. The technique of antigen retrieval from the chip not only removed NCAM off the array 
surface but also some of the mouse antibody. As these were MS samples there were also 
proteins characteristically found in inflammation, such as complement, clusterin, fibrinogen, anti-
thrombin III, platelet factor 4 and human IgG which may have been bound to NCAM. The extent 
of protein binding was more in the serum. 
 
Accession 
 
Entry Description mW 
(Da) 
 
CSF 
 
NCAM1_HUMAN P13591 Neural cell adhesion molecule 1 Homo sapiens 94515 
CLUS_HUMAN P10909 Clusterin Homo sapiens 52461 
FIBB_HUMAN 
 
P02675 
 
Fibrinogen beta chain Homo sapiens 55892 
 
FIBG_HUMAN 
 
P02679 
 
Fibrinogen gamma chain Homo sapiens 51478 
 
IGKC_MOUSE P01837 Ig kappa chain C Mus musculus 11770 
IGG2B_MOUSE 
 
P01867 
 
Ig gamma 2B chain C Mus musculus 44231 
 
KV4A1_MOUSE 
 
P01680 
 
Ig kappa chain V IV Mus musculus 13825 
 
 
SERUM 
 
NCAM1_HUMAN 
 
P13591 
 
Neural cell adhesion molecule Homo sapiens 94515 
 
CO3_HUMAN 
 
P01024 
 
Complement C3 Homo sapiens 187029 
 
CO4A_HUMAN 
 
P0C0L4 
 
Complement C4 A Homo sapiens 192649 
 
C1QC_HUMAN 
 
P02747 
 
Complement C1q subcomponent subunit C Homo 
sapiens 
25757 
 
CLUS_HUMAN 
 
P10909 
 
Clusterin Homo sapiens 52461 
 
VTNC_HUMAN 
 
P04004 
 
Vitronectin Homo sapiens 54271 
 
APOA1_HUMAN 
 
P02647 
 
Apolipoprotein A I Homo sapiens 30758 
 
PLF4_HUMAN 
 
P02776 
 
Platelet factor 4 Homo sapiens 10837 
 
ANT3_HUMAN 
 
P01008 
 
Antithrombin III Homo sapiens 52568 
 
IGG2B_MOUSE 
 
P01867 
 
Ig gamma 2B chain C Mus musculus 44231 
 
IGKC_MOUSE 
 
P01837 
 
Ig kappa chain C Mus musculus 11770 
 
KV4A1_MOUSE 
 
P01680 
 
Ig kappa chain V IV Mus musculus 13825 
 
IGHA2_HUMAN 
 
P01877 
 
Ig alpha 2 chain C Homo sapiens 36503 
 
IGKC_HUMAN 
 
P01834 
 
Ig kappa chain C Homo sapiens 11601 
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Figure 2-6 SELDI-TOF NCAM mass spectra in paired CSF and sera. Paired CSF (A, C, and E) 
and serum (B, D, and F) samples, G recombinant NCAM (positive control), H BSA only (negative 
control) were applied to RS100 arrays. Representative high mass spectra are shown. Doubly- 
charged proteins are in green. 
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Figure 2-7 A map of NCAM sequence coverage generated using ESI-QTOF analysis. 
Regions of the proteinsequence that match peptides are highlighted in grey with their 
corresponding domains marked in red. 
 
 
 
Figure 2-8 Western blot analysis of CSF NCAM (3 samples). A pattern of bands between 
100 and 200 kDa was observed. 
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2.6.3  ESI Q-TOF MS analysis 
 
Characterization of protein retrieved from the chips by ESI Q-TOF MS 
corresponded to sequence motifs from the extracellular Ig-like C2-type 1-5 
domains, fibronectin type-III 1, 2 domains, and the intracellular cytoplasmic 
domain of NCAM (Figure 2-7). This suggests that it is possible to have the 
entire length of the NCAM polypeptide in the CSF. Further analysis by western 
blot showed three polypeptide bands with an apparent molecular weight range 
of 100 to 220 kDa in line with earlier findings. The 120 kDa band was the 
predominant band visualized but was also diffuse. Their relative proximity to 
each other suggests that they are isoforms of NCAM (Figure 2-8). 
 
2.6.4 Development of the NCAM ELISA 
 
Optimisation of the NCAM ELISA to provide a very sensitive signal involved 
manipulation of reagent concentrations, blocking agents and incubation period. 
The working concentrations of the rNCAM and monoclonal capture antibody 
reagents in the assay were optimised through the use of checkerboard titrations 
(CBT) 150. The process of CBT involves a series of experiments in which the 
concentrations of two reagents are varied against each other in order to 
examine the activity ensuing from all resulting combinations. Final 
concentrations of the two reagents were then selected based on the 
combination(s) which provided the best signal: noise ratio. The CBT results for 
rNCAM and capture antibody are presented in tabulated format (Table 2-3). The 
titration results show the levels of binding of the serially-diluted rNCAM to the 
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serially diluted immobilised anti-NCAM. The optimal values of antibody and 
rNCAM dilutions are in blue, optical readings of 2.5 and greater were above the 
photometric accuracy for the FLUOstar Omega plate reader used for this study 
and were therefore excluded. A working dilution of rNCAM of 500 ng/ml and 
monoclonal anti-NCAM antibody of 2.5 μg/ml were chosen as this combination 
allowed for a lower capture antibody concentration. For the polyclonal anti-
NCAM antibody and anti-species antibody a working dilution of 1:1000 was 
accepted (Figures 2-9, 2-10). Also, a variety of blocking buffers were compared 
in the ELISA: 2% BSA, 2% gelatin and 5% dried skimmed milk, in order to 
reduce non-specific binding and increase sensitivity. The colour development 
was faster with the BSA and gelatin as blocking buffers, but the background 
signal was lower with the 5% dried skimmed milk, which was therefore selected 
for use in the assay (Figure 2-11). To complete the assay, optimal incubation 
times were determined: coating performed overnight at 4oC, antigen incubation 
performed overnight at 4oC, whilst the incubation with the detector antibody was 
for 1 h at room temperature and the anti-species reporter antibody was for 1.5 h 
at room temperature. 
 
 
Table 2-3 Double-checkerboard titration experiments carried outwith anti-NCAM and 
rNCAM. The optimal combinations of rNCAM and capture antibody are highlighted in blue. 
 
    Capture Antibody (μg/ml) 
    20 10 5.0 2.5 1.25 0.63 0.31 0.16 
rN
C
A
M
 (n
g/
m
l) 2000 3.434 3.302 3.212 2.317 0.510 0.087 0.050 0.045 
1000 3.370 3.245 3.280 2.422 0.572 0.077 0.054 0.043 
500 3.424 3.279 3.218 2.074 0.421 0.096 0.056 0.053 
250 3.447 3.290 3.105 1.605 0.289 0.079 0.061 0.046 
125 3.193 2.654 2.087 1.455 0.207 0.078 0.049 0.054 
62.5 2.559 2.116 1.864 0.736 0.162 0.070 0.050 0.046 
31.3 1.948 1.397 1.199 0.428 0.137 0.087 0.076 0.059 
  Blank 1.183 1.007 0.541 0.189 0.115 0.064 0.051 0.053 
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Figure 2-9 NCAM standard curves at varying concentrations of detector antibody. 
Polyclonal detector antibody at 1:1000, 1:1500 and 1:2000 dilutions were used with 1:1000 
dilution being best. 
 
 
Figure 2-10 NCAM standard curves at varying concentrations of anti-species labeled 
antibody. Antibody was used at dilutions of 1:1000, 1:2000 and 1:3000. 
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Figure 2-11 NCAM standard curves using different blocking solutions. Semi-skimmed milk 
(5%) gave the lowest assay background. 
 
 
 
Figure 2-12 Typical NCAM calibration curve. 
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2.6.5 NCAM immunoassay characteristics 
 
A typical calibration curve for the NCAM assay is shown in Figure 2-12, the 
minimum detectable concentration was 14.86 ng/ml (this was derived from 
twenty replicates of the zero concentration sample and the apparent 
concentration at two standard deviations from the mean was determined). 
Precision of the NCAM assay was assessed throughout its working range. 
Table 4 shows the intra-assay and inter-assay precision expressed as 
coefficient-of-variation (CV%) at each concentration level and the variability of 
observations for the quality control performed over twenty days was found to be 
within two standard deviations (SD) of the expected concentration for all but two 
of the readings performed on days 4 and 11 (Figure 2-13). 
 
I found the concentration-response relationship of NCAM in the CSF matrix to 
be similar to that in the substitute standard curve matrix to allow extrapolation of 
sample concentrations in the range of the standard curve (Figure 2-14).  
 
 
Table 2-4 Precision profile for the NCAM ELISA (SD, CV%). Table shows the intra-assay 
(repeatability) and inter-assay (within laboratory) precision in standard deviation (SD) and 
coefficient of variation (CV, %) of the ELISA over the range of concentrations analysed. 
 
NCAM concentration 
(ng/ml) 
n Intra-assay Inter-assay 
SD CV SD CV 
15.6 5 0.5 3.3% 1.4 9.2% 
31.3 5 1.0 3.1% 1.5 4.6% 
62.5 5 1.7 2.7% 2.8 4.5% 
125 5 3.7 2.9% 4.3 3.5% 
250 5 11.4 4.5% 14.2 5.7% 
500 5 14.2 2.8% 18.9 3.8% 
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Figure 2-13 Levey-Jennings precision plot of variability in NCAM values by day. QC limits 
were set at mean ± 2SD. The plot demonstrates that there are no systematic errors in analytical 
runs. 
 
The stability of NCAM in CSF after freeze-thaw, bench-top and freezer storage 
was examined. Triplicate aliquots of study CSF were frozen at -80oC and then 
taken through five repeated freeze/thaw cycles, and also stored at ambient 
temperature, refrigerator (+4oC), and -20oC for a seven-day period. Analysis 
revealed a good freeze/thaw and storage stability of CSF NCAM under these 
conditions (Figure 2-15). Lastly, four CSF samples were spiked with the 500 
ng/ml top standard in a 1:1 ratio, and the recovery calculated as a ratio between 
the measured and expected values (Table 2-5). The mean recovery was 
100.6% (range 88-104%). 
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Figure 2-14 Parallelism between NCAM in the reference calibrator and the CSF. Serial 
dilutions of CSF across the working range of the assay shows good parallelism with the 
reference standard suggesting that CSF NCAM corresponds exactly with those in the assay 
calibrators. 
 
Figure 2-15 NCAM freeze/thaw and storage stability (below). 
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CSF sample 
NCAM values 
Unspiked (ng/ml) Spiked observed 
(ng/ml) 
Spiked expected 
(ng/ml) 
Observed/Expected 
(%) 
1 569.4 470.8 534.7 88.0 
2 645.7 560.9 572.8 97.9 
3 511.3 502.4 505.6 99.4 
4 262.1 397.96 381.0 104.4 
 
Table 2-5 Spike and recovery of NCAM in CSF samples. Expected values were calculated by 
adding endogenous NCAM values, from unspiked samples to those of spiked diluent control 
(i.e. standard). Percentage recovery was determined by dividing observed by expected values.  
 
2.6.6 CSF NCAM values in neurological disorders are a potential 
prognostic indicator of neuronal plasticity 
 
The mean NCAM values ± SD (ng/ml) were 308 ± 101 (BIH), 250 ± 107 (MS), 
307 ± 109 (neuropathy), 250 ± 98 (AD), 293 ± 83 (CI), 357 ± 140 (MND), 170 ± 
127 (meningitis), 515 ± 193 (viral encephalitis), and 412 ± 109 (controls) (Figure 
2-16). The differences in mean NCAM values among the different categories 
were statistically significant (p<0.001) by one-way ANOVA. There were 
significant differences between the control and MS, AD and meningitis 
categories which had the lowest mean NCAM values. The viral encephalitis 
category were also found to be significantly different from all other diagnostic 
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categories examined except for controls; with HIV encephalitis/cryptococcal co-
infection contributing to the very high levels (757-886 ng/ml), followed by HSV 
encephalitis (495-749 ng/ml). No significant differences were found regarding 
mean age (p=0.06), or sex (p=0.113). The mean albumin quotient and IgG 
index were 0.68 mg/l (range 0.12 – 3.35 mg/L) and 1.01 mg/l (range 0.26 – 6.84 
mg/L), respectively. There was no correlation between the albumin quotient 
measures (r=0.20, p=0.13) and IgG index (r=-0.17, p=0.21) and CSF NCAM 
levels. 
 
Further sub-group analysis of neuropathies into Guillain-Barré Syndrome 
(GBS), polyneuropathy, hereditary motor and sensory neuropathy (HMSN) gave 
mean NCAM values of 286 ± 80 ng/ml, 285 ± 117 ng/ml, 384 ± 99 ng/ml, 
respectively. Polyneuropathy was found to be significantly lower than controls 
(p=0.01) but did not differ from either GBS or HMSN. MS was sub-divided into 
clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), secondary 
progressive MS (SPMS) and primary progressive MS (PPMS) with mean NCAM 
values of 393 ± 83 ng/ml, 259 ± 87 ng/ml, 193 ± 97 ng/ml, 284 ± 32 ng/ml, 
respectively. Both RRMS (p<0.001) and SPMS (p<0.001) had NCAM values 
significantly lower than controls, whilst CIS was found to have higher values 
than RRMS (p=0.03) and SPMS (p<0.001). No inter-category differences were 
found between PPMS and the rest.  
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Figure 2-16 Quantification of NCAM in selected neurological disorders. Low NCAM values 
were measured in MS, AD and meningitis (P<0.001) when compared to controls. Viral 
encephalitis was significantly different from other neurological disorders but not controls. 
 
2.6.7 NCAM antigen-specific antibodies in serum/CSF 
 
NCAM antigen-specific antibodies were present in some of the MS serum 
samples tested but not all (Figure 2-17A). Conversely, out of the 50 CSF 
samples tested only one sample gave rise to a weakly positive result (marked 
by * in Figure 2-17B). 
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Figure 2-17 Western blots of NCAM antigen-specific antisera in MS and control samples. 
A) Serums. A strongly positive band was seen with serum 1 (lane 3), whilst serums 2, 3 (lanes 
4, 5) displayed weakly positive bands. Serums 4-6 (lanes 6-8) were negative. B) CSFs. A 
weakly positive band was visible with CSF 2 (lane 4, marked by *), the remaining CSF samples 
were negative (lanes 3, 5-8). 
 
2.7 Discussion 
 
Immunocapture protein profiling by SELDI-MS has shown similarities and 
differences in NCAM in CSF compared to serum. In the CSF at least there is a 
restricted pattern of expression, indicating that the CSF composition of NCAM is 
intrathecal-specific. Under physiological conditions proteins within the CSF 
circulate into the vascular system, and as the CSF contains less protein 
compared to serum, any local differences are likely to be reduced in the serum. 
This was not evident in our paired CSF samples suggesting that other non-
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neuronal tissues probably also contribute to serum NCAM composition. NCAM 
is predominantly expressed in the CNS in neurons and glial cells; however, it is 
also present in skeletal muscle, adrenal medulla, developing kidney, pancreatic 
islet cells and CD56 NK cells and may explain the soluble NCAM in the sera 144; 
151; 152; 153; 154; 155. The spectra of mass-to-charge ratios generated from a sample 
by SELDI-TOF MS do not infact identify proteins in that sample; however, by 
shotgun protein sequencing I was able to confirm the presence of NCAM within 
them. Subsequent ESI Q-TOF MS analysis of the CSF protein digest, however, 
was able to advance this further by providing information on potential NCAM 
isoforms candidates in the CSF through assessment of peptide sequence 
coverage. The extracellular segment as well as the intracellular cytoplasmic 
portion of NCAM was identified indicating that it is possible for all three isoforms 
of NCAM to be present in the CSF. A concept further supported by the western 
blot data where bands ranged from 115 – 220 kDa supporting the shedding of 
intact transmembrane isoforms. NCAM-120 has been described as the 
predominant size in the CSF using approximate sizing against molecular weight 
markers and owing to its largely extracellular configuration 104; 108. Cox et al. 
provide evidence of ectodomain shedding of an extracellular 105-115 kDa 
fragment (NCAM-EC) and a smaller 30 kDa intracellular fragment (NCAM-IC) 
thought to be derived from the cytoplasmic domain of NCAM-140 52. Whilst 
Olsen et al. demonstrated shedding of the transmembrane NCAM in intact 
soluble form from membranes of cells transfected with this isoform 142. 
Furthermore secretion studies timing the secretion of NCAM into neuronal cell 
culture medium demonstrated that this occurred 15-20 min before the 
accumulation of NCAM on the cell surface suggesting that soluble NCAM 
contains a secreted component 75. 
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I have chosen to look at CSF NCAM as it is most closely related to the brain 
and likely to be representative of brain pathology. Although soluble forms of 
NCAM have been observed in culture media and body fluids, it is unclear 
whether they have any biological role 131; 142; 143; 144. It is postulated that soluble 
NCAM interferes with homophilic adhesion between membrane bound NCAM 
resulting in de-adhesion and thereby modulating NCAM-dependent neuronal 
growth. In vitro evidence from Olsen et al. 142 demonstrated that soluble NCAM 
inhibited cell binding to an immobilised NCAM substratum. Specific inhibition of 
NCAM release from the membrane by blocking metalloproteinase cleavage 
(using inhibitors BB-3103 or GM 6001) resulted in aggregation of neurons in 
primary hippocampal neurons in culture and NCAM-140 expressing B35 
neuroblastoma cells 156; 157.  
 
In this chapter, I have reported on an ELISA method for measuring NCAM 
levels in the CSF using readily obtainable commercial reagents. The ELISA was 
able to detect NCAM levels in a sensitive and reproducible manner. I also 
provide results on the distribution of NCAM levels in a variety of neurological 
disorders that suggest that NCAM measurements may be useful in quantifying 
capacity for repair in the nervous system. Previous groups have published work 
using NCAM ELISA 98; 137, however, without reference to assay validation and to 
my knowledge this is the first description of an ELISA using commercially 
available reagents.  
 
Using this ELISA I found low NCAM levels in the CSF of MS, Alzheimer’s 
disease and meningitis patients. We found the levels were independent of age 
and gender. It is possible that the low NCAM levels represent extensive 
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neuronal damage or a lowered potential for endogenous repair in these 
disorders due to chronicity or neurodegenerative aetiology. This is further 
substantiated by the sub-category analysis where low levels of NCAM were 
found in polyneuropathy compared to GBS and HMSN, and also SPMS (the 
progressive form of MS), in particular, and RRMS compared to CIS (early MS). 
Others have similarly demonstrated reduced NCAM levels in the CSF of MS 
patients, but not AD 98; 148. Work by Thomaidou et al. 158 indicated involvement 
of soluble NCAM in Schwann cell migration and a lack there of in chronic MS 
and may be an important factor to take into account when looking at 
remyelination strategies. Conditions where no significant differences were noted 
from controls were BIH, CI, MND and viral encephalitis. However, the latter was 
the only category where very high levels were recorded, a few much higher than 
the control range. More extensive analysis using a larger sample size is 
required to investigate this further. Little in fact is understood about neuronal 
turnover in CNS infections, previous work in rabies have shown that the virus 
mediates entry at the neuromuscular junction via the NCAM receptor and that 
cells susceptible to rabies infection also express NCAM on their surface 159. 
Whether other viruses are capable of a similar mode of entry is not known. 
Another possibility is that high NCAM levels are an indication of natural killer 
cell activity, as NCAM in neuronal surfaces is virtually identical to the CD56 
leukocyte antigen found on the surface of Natural Killer (NK) cells and I may be 
indirectly measuring this in the CSF. 
 
I found no correlation between CSF NCAM levels and CSF/serum albumin 
ratios suggesting that CSF NCAM was not the result of passive transfer of 
NCAM from serum to CSF following blood-brain barrier dysfunction. The 
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evaluation of local IgG production (IgG index) in these samples showed no 
relationship with CSF NCAM levels indicating that a rise in NCAM (a member of 
the immunoglobulin superfamily) levels was not a phenomenon similar to the 
local increase in the IgG index observed in the CSF of patients with multiple 
sclerosis 160. In this study, I found anti-NCAM antibodies in some of the MS 
patient sera which have the potential to interfere with the detection of NCAM in 
ELISAs. In the samples tested, only one of the CSF samples tested gave rise to 
a weakly positive band. One possible explanation might be that there is a 
dilutional effect of antibodies in the CSF and if present at small quantities, may 
not be visible by western blotting. However, more work is needed to determine 
whether the anti-NCAM antibodies present in serum have the ability to inhibit 
the detection of NCAM in an ELISA system; this may depend on the affinity of 
the antibodies involved, the sharing of epitopes, and the concentration of anti-
NCAM antibodies. 
 
In conclusion, my preliminary work points to interesting findings about soluble 
NCAM and how it varies between different neurological conditions. Using SELDI 
MS and ESI Q-TOF MS analysis I was able to demonstrate that NCAM is 
present in similar quantities in the CSF as well as serum, the composition of 
isoforms is both extracellular and intracellular, and the total levels are 
comparatively lower than expected in MS, Alzheimer’s disease and meningitis. 
This may be a reflection of the extent of neuronal injury or underlying 
neurodegenerative aetiology, or both. Therefore, low NCAM levels may not be 
unique to a particular disorder, they may however, have an overall prognostic 
significance. 
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3 Progression in multiple sclerosis is associated with 
low endogenous NCAM in models 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
3.1 Introduction 
 
MS is the prototypical inflammatory demyelinating CNS disorder. It has a varied 
onset and disease course, but progression is the ultimate outcome in the 
majority of cases. New concepts in pathogenesis have emerged and include 
theories on axonal degeneration as a prerequisite for progression and 
remyelination and repair as being important for recovery 161; 162; 163. 
Remyelination is a frequent finding at the edges of most chronic plaques but 
absent within its centres 82. It is a consistent feature in early lesions exemplified 
by shadow plaques (Figure 3-1) 80. Axonal plasticity, however, is less well 
documented. Many argue that adult CNS does not spontaneously regenerate 
after injury, a view that has been prevalent for over a century (S. Ramon Y 
Cajal, 1989) 26. However, functional plasticity has been visualised in MS 
patients using fMRI despite a high burden of cerebral pathology 164. 
 
 
 
Figure 3-1 Remyelination in MS. A shadow plaque in MS demonstrating Remyelination 
(arrows). The histologic section was immunostained for myelin basic protein. Image courtesy of 
Dr K Schmierer, London, UK. 
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In order to be able to recapitulate developmental events for neuronal growth 
and to enable response to guidance cues, the regenerating axon needs to 
express the correct complement of cell surface molecules. A plethora of cell 
adhesion molecules have been identified, but the neural cell adhesion molecule 
(NCAM) is one of the most-widely studied and best characterised, being 
intimately linked to the process of axonal outgrowth, guidance and fasciculation 
47; 123; 124; 165. It not only serves as “glue” in cell-cell adhesion and contact-
mediated attraction, but also interacts with a number of heterophilic binding 
partners such as fibroblast growth factor receptor (FGFR) 166, adhesion 
molecule L1167, ATP 168, prion protein (PrP) 169, and has also been recently 
suggested to regulate signalling via the receptors for other growth factors; brain-
derived neurotrophic factor (BDNF) 170, glial cell line-derived neurotrophic factor 
(GDNF) 171; 172, platelet-derived growth factor (PDGF) 173, and epidermal growth 
factor receptor (EGFR) 174. This ability to interact with multiple binding partners 
may lead to diverse results based on the potential complexes formed. 
 
Evidence from NCAM-null mice suggests that though NCAM is not essential for 
survival, they demonstrated a reduction in olfactory bulb size, abnormal 
fasciculation of hippocampal mossy fibres and a deficiency in long term 
potentiation 49; 51; 175. More recent work, however, clearly demonstrates severe 
hypoplasia of the long axonal projection, the corticospinal tract 176, and 
pronounced alterations in the recycling of synaptic vesicles at the 
neuromuscular junction, with an inability to sustain high-frequency nerve 
transmission 58. MS patients enter a progressive phase characterised by 
primarily motor deficits in walking, this is largely attributable to dysfunction in the 
long spinal tracts, which have lesser likelihood of instituting successful repair 
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and reinnervation following injury, and NCAM may have an important role to 
play in locomotor recovery. Moreover, NCAM has been shown to be involved in 
contact-mediated axon-glial signalling influencing the survival and outgrowth of 
oligodendrocytes following contact with the axon during myelination 122. Whilst, 
double MAG (myelin-associated glycoprotein)/NCAM knockouts demonstrate 
pronounced axonal pathology even in the absence of overt dysmyelination, 
possibly by altering the function of specialised membranes such as lipid rafts, 
and thus disturbing the functional integrity of axons leading to axonal injury 177. 
 
Experimental autoimmune encephalomyelitis (EAE) has long been used as an 
animal model of MS. It is primarily a T-cell mediated disease and is dominated 
by macrophage-mediated inflammation at the end stage 178. Depending on the 
antigen and mode of sensitisation different aspects of MS pathology can be 
produced. Axonal loss occurs with each relapsing attack and probably 
continues into the chronic progressive phase, alluding to a causal relationship 
between inflammation, axonal degeneration, and irreversible neurological 
disability 179; 180. In contrast, limited repair of myelin damage can be achieved 
181, but structural reconnection and functional repair can only be achieved early 
in the disease in the presence of sufficient reserve capacity 182. The EAE model 
therefore presents an opportunity for determining the impact of inflammation 
and axonal degeneration on means of recovery in MS. Another route to explore 
this aspect further is through in-vitro neuronal culture models; previously 
demyelinating mechanisms related to MS have been studied in neuronal cell 
cultures from foetal rat brain. Exposure to anti-myelin oligodendrocyte 
glycoprotein (α-MOG) has been shown to result in demyelination, and MBP 
synthesis resumes following removal of demyelinating agents predictably, 
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providing a unique model to study the effects of demyelination on axonal 
plasticity 183; 184. 
 
3.2 Aims 
 
The preliminary findings from chapter 2 point toward NCAM possibly being 
lowered after neuronal injury or neurodenegeration, and I wanted to test this 
further in models of neuronal injury in order to elucidate the molecular 
processes that take place in greater detail. The aim of this chapter was to 
investigate the impact of inflammation/demyelination and axonal injury on 
NCAM using in-vitro culture and EAE models.  
 
In order to achieve this, NCAM was quantified by ELISA in CNS neuronal 
aggregates over time and under demyelinating experimental conditions to study 
its effect on axonal plasticity. 
 
Further assessments of NCAM levels were carried out in acute and chronic 
EAE models to obtain an insight into the endogenous reserve capacity of 
inflammatory CNS disorders. 
 
3.3 Materials and methods 
 
NCAM concentrations were determined in neuronal aggregates and mice spinal 
cord tissues by a modification of the method for the commercial sandwich 
enzyme-linked immunoassay from R&D Systems (#DY2408). The assay was 
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suitable for the analysis of cell culture supernatants and detected NCAM 
concentrations in the picogram (pg)/ml range required for this portion of the 
work. Assay reproducibility was checked prior to use. 
 
The rat CNS neuronal aggregate system was maintained by Dr Sam Jackson, 
Blizard Institute, Queen Mary University of London. Serum free, rotation-
mediated neuronal aggregate cultures were prepared from foetal Sprague 
Dawley rat telencephalon (adult timed pregnant rats were obtained from 
Charles River, Margate, Kent) as previously described 183; experiments were 
performed in accordance with the UK Animals (Scientific Procedures) Act 1984, 
under the control of the UK Government Home Office. Preparative steps are 
detailed below. A list of solutions used can be found in the Appendix to Chapter 
3. 
 
EAE induction in SJL/J (using active immunization with proteolipid protein-
residues 139-151 peptide in Freunds complete adjuvant) and C57BL/6 mice 
(using active immunization with MOG-residues 35-55 peptide in Freunds 
complete adjuvant), representative of relapsing-remitting and chronic EAE, 
respectively, were performed by Dr Peggy Ho, Department of Neurology and 
Neurological Sciences, Stanford University School of Medicine, CA. Female 
SJL/J and C57BL/6 mice were obtained from The Jackson Laboratory (Bar 
Harbor, ME, USA). All animal protocols were approved by the Division of 
Comparative Medicine at Stanford University School of Medicine, in accordance 
with the National Institutes of Health guidelines. 
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3.3.1 The rat CNS aggregate cell culture system 
 
Pregnant rats were sacrificed by decapitation at the age where their foetuses 
were 16 days old; the embryos were removed and placed in sterile ice-cold D1 
solution (see 3.6.1). The foetal telencephalons were dissected out. After 
washing twice in D1 solution, brain tissue was progressively dissociated by 
sieving through a 200 μm pore followed by 115 μm pore nylon mesh (Nybolt, 
Zurich, Switzerland). The filtrates were centrifuged at 300 x g for 15 min at 4oC 
and tested for viability using 0.1% trypan blue exclusion and then re-
centrifuged. The remaining telencephalon cell population was seeded at 4 x 107 
cells per flask and incubated at 37oC in a humidified 10% CO2/ 90% O2 
atmosphere (Heraeus incubator, Philip Harris Scientific, UK) under continuous 
rotation (Kuhner Shaker, Philip Harris Scientific, UK). The rotation speed was 
increased from 0.15 to 0.18 g over the first week of incubation to enable optimal 
cell aggregation. The day of seeding was termed ‘Day In-Vitro’ zero (DIV 0). 
Cells were subsequently transferred to larger flasks on DIV 2, and the DMEM 
(Gibco BRL) was doubled to 8 ml. On DIV 5, 8, 11, 14 and subsequently every 
other day, cultures were fed by replacing 5 ml of pre-warmed DMEM in each 
flask (Figure 3-2).  
 
3.3.1.1 Demyelination protocol 
 
Z12 mouse IgG2a-MOG specific antibody (a gift from P. Smith, NL) plus 
complement (guinea pig serum, Serotec) was added to pre-warmed culture 
medium, whilst control cultures received either medium alone or IgG2a (Sigma) 
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as an IgG control were added at DIV 25 for 72 h.  Cultures were maintained as 
normal, substituting medium for supplemented medium on DIV 21 and 23. 
Antibody was removed by medium replacement three times on DIV 29. Control 
flasks were also subjected to triple medium replacement. 
 
 
 
 
Figure 3-2 Steps detailing the preparation of rat CNS neuronal aggregate cultures. 
Embryonic E16 rat brain were dissected and dissociated mechanically by sieving. Dissociated 
cells form aggregates maintained as rotation-mediated free floating aggregate cultures. 
 
3.3.1.2 Sampling of aggregates 
 
For analysis by ELISA aggregates were sampled at various time points DIV 25 
– 40. They were homogenised for 30 s in 1:20 (w/v) Tissue Protein Extraction 
Reagent (T-PER, Pierce) with protease inhibitors at 20:1 (w/v) (Protease 
inhibitor cocktail, Sigma). Samples were then centrifuged at 1520 x g to remove 
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particulate material, and insoluble material was discarded. Total protein content 
was assayed using the Bio-Rad protein assay: 25 μl of reagent A was loaded 
into each well of a microtitre plate, followed by 10 μl of protein standard 
containing 0.063 mg/ml to 2 mg/ml protein and samples, and then 200 μl 
reagent B. The plate was then left to stand at room temperature for 10 minutes 
with agitation to mix the reagents and the final absorbances were read at 750 
nm. The standards were plotted and the total protein value calculated from the 
standards. Samples were assayed in batches and stored at -80oC.     
 
3.3.2 Induction of EAE in SJL and C56BL/6 mice 
 
Female SJL/J and C57BL/6 mice were immunised at 8-10 weeks of age with 
0.1 mg PLP 139-151 (SJL) or MOG 35-55 (C57BL/6) in PBS emulsified in 
Complete Freund’s Adjuvant (CFA) and were boosted intravenously with 400 ng 
Bordetella pertusssis Toxin (List Biological Laboratories, Campbell, CA) on days 
0 and 2. Animals were examined daily for clinical signs of EAE and scored as 
follows: Grade 0, healthy; Grade 1, tail paralysis; Grade 2, hind limb 
paraparesis; Grade 3, hind limb paralysis; Grade 4, complete paralysis 
(tetraplegy); and Grade 5, death. A relapse was defined as an increase in one 
grade or more in the EAE scale, sustained for at least two consecutive days. At 
the times indicated, mice were euthanized and perfused with 40 ml ice-cold 1x 
PBS before brains and spinal cords were dissected and snap frozen for further 
analysis. Spinal cords were collected at specific stages of disease (see results 
section Figure 3-3 & Table 3-1).  
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Subsequently, spinal cords were mechanically homogenised in T-PER (Pierce) 
at 1:20 (w/v) of tissue to reagent on ice until all visible aggregates had 
disappeared. Homogenates were then centrifuged at 1520 x g for 30 min to 
remove particulate material, and insoluble material was discarded. To the 
resulting supernatants protease inhibitors (Protease inhibitor cocktail, Sigma) 
were added at 20:1 (w/v). Total protein content was determined as above. 
Samples were stored at -80oC and assayed in batches. 
  
3.3.3 R&D NCAM ELISA Protocol (#DY2408) 
 
3.3.3.1 Plate preparation 
 
Capture antibody at 2.0 μg/ml concentration in PBS, pH 7.4 (Sigma) without 
carrier protein were coated onto polystyrene Nunc-MaxiSorpTM 96-well plate 
overnight at 4oC. Afterwards, wells were washed once with PBS containing 
0.05% Tween 20 (Sigma) and blocked with 300 μl 1% bovine serum (Sigma) in 
PBS and left for 1 hr at room temperature on a plate shaker to saturate the 
wells thoroughly and prevent non-specific binding of antigen. The plate was 
then rinsed with PBS-Tween.  
 
 
 
3.3.3.2 Assay procedure 
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200 μl of sample or standards diluted in 50 μl of reagent diluent containing 1% 
bovine serum in PBS were applied to each well and incubated for 2 h at room 
temperature on a plate shaker. The final dilutions of the standard curve ranged 
from a top-standard of 2500 pg/ml to 156 pg/ml using two-fold serial dilutions in 
reagent diluent. Again, the wells were washed three times with PBS-Tween 
followed by the addition of 100 μl of the detection antibody at a final 
concentration of 200 ng/ml diluted in reagent diluent. After 2 h incubation at 
room temperature with shaking, wells were re-washed three times with PBS-
Tween. 100 μl of streptavidin-HRP solution at a dilution of 1/200 (R&D Systems) 
in reagent diluent was applied to the wells and incubated for 20 min with 
shaking at room temperature (plate was covered to avoid exposure to light). 
After washing as before, 100 μl of substrate solution (1:1 admixture of Hydrogen 
Peroxide and Tetramethylbenzidine) was added and incubated for 10 min in 
darkness. The reaction was stopped by the addition of 50 μl of 2 N H2SO4 
solution per well. The optical density at 450 nm with wavelength correction at 
540 nm was read with a FLUOStar Omega plate reader (BMG Labtech). 
Sample values were calculated from the NCAM antigen standard curve and 
corrected by deducting blank values from wells coated with 1% bovine serum 
(zero standard). NCAM values were converted to per mg of protein based on 
previously calculated total protein measurements for the samples. 
 
 
3.3.4 Statistical analysis 
 
Neuronal culture analyses were performed using SPSS (version 16) statistical 
software. Before proceeding, the data were assessed for normality using 
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Shapiro-Wilk test. NCAM values were log-transformed and differences in mean 
NCAM values were tested for significance by one-way ANOVA with post hoc 
comparisons conducted using Tamhane test for unequal variances (the alpha 
was set at 0.05). EAE analysis was performed using GraphPad Prism (version 
5) software, with Kruskal-Wallis test and Dunn’s post hoc evaluation.  
 
3.4 Results 
 
3.4.1 Differential modulation of NCAM during development and 
following demyelination 
 
In neuronal aggregates, NCAM concentrations decreased in all three 
experimental groups over the lifespan of the aggregate cultures suggesting a 
developmental reduction in the protein, a finding which is consistent with its role 
in axonal growth and plasticity (Figure 3-3). The introduction of the 
demyelinating agent α-MOG mAb at the optimum age of the cultures (DIV 25) 
resulted in a significant reduction in NCAM afterwards (Figure 3-3). A 
demyelinating insult therefore also results in changes to the underlying axon. By 
DIV 40, NCAM levels were comparable to those of control experiments, 
suggesting that the effect was reversible. 
 
 
 
89 
 
 
Figure 3-3 NCAM expression during demyelination and repair in 3D neuronal cultures. 
Neuronal aggregate cultures from rat telencephalon were grown and these were demyelinated 
by the addition of a MOG-specific antibody and complement or a non-binding mouse IgG2a 
control antibody on day. The results represent the mean NCAM (pg/mg) ± SE at day in vitro 
(DIV) 25, 29, and 40 and following demyelination with α-MOG. 
 
3.4.2 Persistent reduction of NCAM in chronic EAE 
 
NCAM was investigated in SJL and B6 mice that exhibit a relapsing-remitting 
disease course and a chronic course in EAE, respectively (Figure 3-4). There 
was a significant drop in NCAM levels in acute EAE at the peak of the disease 
in both models compared to naive animals suggesting a comparable 
pathophysiology. Similarly, during the chronic phase of the disease NCAM 
levels remained low in both models suggesting that there was no recovery in 
NCAM levels by this point. Although not statistically significant, during remission 
stages in the spinal cords of the SJL mice, an upward trend in mean NCAM  
 
P<0.05 
P<0.05 
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Figure 3-4 Neurological course of EAE in mice. SJL mice were sensitised with PLP peptide 
or C57BL/6 mice were sensitised with MOG peptide in Freunds adjuvant on day 0. The results 
represent the mean daily clinical score ± SEM (n ≥ 8). The approximate timing of each disease 
phase relative to disease in SJL mice is shown. 
 
Table 3-1 Clinical disease scores of EAE in SJL and C57BL/6 mice during the different 
phases of EAE. 
  
 Naive/CFA 
D21/D21 
Acute 
D14/D18 
RM1 
D21/D21 
Relapse 
D26 
RM2 
D52 
Chronic 
D80/D52 
SJL 0.0 ± 0.0 3.9 ± 0.1 1.1 ± 0.3 3.0 ± 0.2 1.5 ± 0.3 2.0 ± 0.0 
C57BL/6 0.0 ± 0.0 2.4 ± 0.4 2.0 ± 0.0 n/a n/a 1.9 ± 0.3 
 
EAE was induced in mice on day 0. The results represent the mean clinical score ± SEM during 
active disease or the minimal score during remission when tissue were sampled for NCAM-
specific ELISA (n ≥ 8). The days of sampling was indicated in white for SJL mice and grey for 
C57BL/6 mice. CFA=complete freund’s adjuvant. 
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Figure 3-5 NCAM levels in spinal cords during EAE. Following the induction of EAE NCAM 
(pg/ml) levels were measured in SJL (top) and C57BL/6 (bottom) mice by ELISA. During EAE 
NCAM content reduced (*P<0.05).  
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levels was apparent (Figure 3-5). CFA also appeared to reduce NCAM content 
(open circles), though not statistically significant. 
 
3.5 Discussion 
 
Axonal recovery following inflammatory or demyelinatory injury requires the 
engagement of axonal signalling molecules in promoting neurite outgrowth. The 
cell adhesion molecule, NCAM, has long been indicated to possess this 
capability, through growth promoting signal transduction pathways conducive to 
axonal regrowth and synaptic plasticity 185. Here in-vitro and in-vivo evidence 
suggesting that NCAM maybe irretrievably down regulated or damaged in the 
injured CNS following inflammation and demyelination is presented. 
Furthermore, this effect may be amplified by the temporal downregulation of 
NCAM with ageing.  
 
Neuronal aggregates of dissociated rat foetal brain neuronal cells form when 
cells are brought in culture at concentration higher than 104 cells/ml, and can be 
used as highly reproducible alternatives to monolayer cultures of neurones 184; 
186. The analysis of NCAM concentration in these neuronal aggregates 
demonstrates the existence of a temporally precise modulation of NCAM 
concentration over time. Although the expression persists into the mature 
aggregates beyond that of what is considered developmental expression, it is 
only a fraction of the original NCAM content. This has obvious implications for 
enhancing repair in the ageing CNS. Antibody-mediated demyelination results 
in a marked reduction in NCAM suggesting acute axonal damage. This is 
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supported by previous work by Jackson et al. who demonstrated that 
demyelination induces immunopositivity to SMI32 antibody in aggregates, a 
marker of changed phosphorylation status in the axon 187. Previous work in 
neuronal aggregates have only investigated the effects of demyelination 
induced by cytokines (TNF-α, IFN-γ and IL-1) or antibody directed against 
myelin (α-MOG) in this system, wherein myelin synthesis resumes following the 
removal of demyelinating agents. Analysis presented here provides evidence 
that short-term exposure to anti-MOG antibody resulting in demyelination also 
adversely affects neuronal plasticity in this aggregate system as well. This effect 
is transient with the NCAM content of aggregates being proportional to that of 
untreated and control cultures by DIV 40.  
 
In EAE, a T-cell mediated inflammatory model, the drop in NCAM concentration 
is immediate and persists into the chronic stages suggesting that the outcome is 
identical despite the differences in aetiopathogenesis. The EAE findings further 
indicate that there is no definite recovery in NCAM levels during periods of 
disease remission and the precise point in the temporal decline in NCAM 
expression that occurs with ageing is reached much sooner than anticipated 
with inflammatory insults. Evidence from natural history studies in MS suggest 
that in patients this occurs during the sixth-decade of life and is unaffected by 
the initial course of MS, whether it be relapsing-remitting or progressive MS 188; 
189. These observations are supported by the results here, wherein the SJL 
mice which exhibit a relapsing-remitting course in EAE and the B6 mice which 
have a more chronic disease course, both demonstrate a similar reduction in 
NCAM concentrations despite their differences in disease pathophysiology. The 
degree and frequency of insult apparently makes little difference to the overall 
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outcome. Axonal injury is now considered a consistent feature of MS pathology, 
with evidence from EAE suggesting that axonal loss determines permanent 
neurological impairment 190. Whilst, there is little information on axonal 
regeneration with the only evidence coming from focal spinal cord injury models 
but not EAE. Often the premise for regeneration is based purely on the 
amelioration of signs of EAE 191; 192. By contrast, remyelination has been 
extensively studied and has been shown to promote functional recovery in 
these models 193. It remains to be seen whether remyelination strategies alone 
can hold back the tide on disease progression. 
 
In summary, demyelination and neurodegeneration characterise the course of 
multiple sclerosis. Although hallmarks of recovery (remyelination) have been 
documented in early MS, the regenerative capacity of the adult CNS remains 
uncertain. NCAM has been widely implicated in axonal outgrowth, guidance and 
fasciculation. Here, in-vitro and in-vivo models of MS were used to investigate 
its role in disease progression. It was evident that NCAM decreases over time 
with ageing in neuronal aggregate cultures and decreases acutely after 
demyelination and after the initial inflammatory episode in EAE, but remains 
reduced with subsequent relapses. This suggests that lower levels of NCAM, 
hence axonal plasticity may be associated with disease progression observed in 
MS. Alternatively, it demonstrates that NCAM was lost as EAE accumulated 
irreversible nerve loss that was associated with the chronic disability. 
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4 Growth Associated Protein (GAP-43):  
Expression, purification and characterisation of 
recombinant GAP-43 protein tagged with V5 and poly 
His for the development of a sensitive quantitative 
ELISA for GAP-43 
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4.1 Introduction 
 
The membrane protein GAP-43 (growth-associated protein of 43 kDa), also 
known as neuromodulin or B-50, was originally isolated in 1980 194 and 
appeared to be a major protein present in synaptic plasma membranes. It is 
found in axons specifically associated with growth cones and immature synaptic 
terminals 59. While GAP-43’s precise function is not known, there are several 
lines of evidence to support for a role in pathfinding in axons. GAP-43 
expression has been found to be greatly increased in growing 195 and 
regenerating axons, and in some mature axons capable of regeneration (i.e. 
those of fish and amphibians), axotomy resulted in a gross upregulation of the 
protein that coincided with, or preceded the initiation of axonal outgrowth 61. 
Knock out mice lacking GAP-43 die early in the postnatal period, as well as 
having axons stall and then take random courses when they reach decision 
points such as the optic chiasm, suggesting that GAP-43 serves to amplify the 
response of growth cones to external cues 63; 196. When GAP-43 is 
overexpressed in mice lesion-induced nerve sprouting and terminal arborisation 
during reinnervation were greatly potentiated 62. 
 
GAP-43 is found exclusively in particulate fractions of brain tissue and absent 
from cytosolic subcellular fractions of peripheral organs 197. Throughout life 
GAP-43 is found in high levels in neocortical association areas and the limbic 
system, presumably localised to areas rich in synaptic contacts 35; 198; 199. Whilst 
in certain brain areas involved in ascending somatosensory information (e.g. 
cochlear nuclei, the vestibular complex or the sensory cortex) and motor control 
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(e.g. red nucleus, the motor nuclei of cranial nerves or the motor cortex), GAP-
43 is essentially absent 200; 201.  
 
In disease, GAP-43 was found to be reduced in a majority of white matter 
plaques in multiple sclerosis (MS), with the exception of remyelinated lesions 
where the expression was increased 111. CSF GAP-43 levels negatively 
correlated with MRI measures of brain atrophy (r = -0.30), a marker of axonal 
injury 111. A close study of the early stages of inflammatory lesions in the CNS in 
an animal model using targeted inflammatory lesions to the corticospinal tract, 
demonstrated that the axons remodelled in response to the lesions by recruiting 
local interneurones and collaterals closely associated with prolonged temporal 
expression of GAP-43. Moreover, behavioural studies showed that recovery 
was closely linked to these changes 182. Reduced GAP-43 levels correlated with 
high neurofibrillary tangle density in Alzheimer’s disease (AD) 202 and end-stage 
AD brains exhibit reduced neuronal expression of GAP-43 203. Positive 
correlation was found between CSF GAP-43 and tau, with significantly reduced 
levels in Parkinson’s disease (PD) 110. These observations suggest shared 
mechanisms in the respective cascades of neurodegeneration in these 
disorders. GAP-43 was reduced in bipolar disorder, the reduction correlating 
with disease duration, whilst in schizophrenic patients it was enriched in the 
visual association and frontal cortices, indicating that increased GAP-43 is 
associated with dysfunctional organisation of synaptic connections in 
schizophrenia 204. GAP-43 plays a crucial role in axonal regeneration in avulsed 
motor neurones with up-regulation as early as day one accompanied by axonal 
regeneration 205. In contrast, regeneration of rubrospinal tracts (CNS) into 
peripheral nerve grafts were detected after cervical and not after thoracic injury 
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with increased GAP-43 present only in the former, indicating that GAP-43 
expression after injury is a prerequisite for CNS axonal regeneration and is 
diminished if the injury occurs farther from the cell body 206. While there is 
evidence to suggest that external administration of growth factors BDNF and 
NT-4/5 into the vicinity of injured rubrospinal neurones stimulated GAP-43 and 
prevented neuronal atrophy 207. Tacrolimus (FK506), an immunosuppressant, 
increased the number of GAP-43 positive neurones after spinal cord injury in 
the rat paralleled by significant improvement in neurological function 208. 
 
GAP-43 can therefore serve as a growth cone marker protein, potentially 
advancing our understanding of regulation of neuronal growth and response to 
disease. CSF GAP-43 is presumably the secreted GAP-43 that is localised in 
presynaptic membranes, but must be permealised for it to be recognised. The 
GAP-43 protein is highly hydrophilic (isoelectric point of 4.3 – 4.5), except for 
the small membrane binding domain and entirely conceivable that it can exist as 
a soluble protein. Qualitative western blot analysis reveals a major band at ~ 50 
kDa (molecular weight range 47 – 53 kDa) 209; 210; 211, densitometric assessment 
of this band is one possible approach to estimating GAP-43 protein content, 
although performing it is cumbersome with inconsistent measures. At the time 
this study was performed, ELISA protocols for GAP-43 utilised partially purified 
protein with the estimation of total protein or simply arbitrary values 199; 212 or 
recombinant protein gifted from another source without the details of production 
109; 110; 111. There was no commercially available recombinant protein as it is 
technically difficult to secrete via a vector expression system since it attaches to 
the inner membrane surface preventing its release 35. 
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4.2 Aims 
 
The aims of the work presented in this chapter were to develop a method for 
producing and purifying recombinant GAP-43, in preparative quantities for use 
in an ELISA system. The GAP-43 was to be as pure as possible, retaining the 
folding and post-translational modifications of authentic GAP-43 and therefore 
maintaining its antigenicity towards anti-GAP-43 antibodies.  It would then be 
used as the standard in a quantitative ELISA for detecting CSF GAP-43 in 
neurological disorders. The chapter also describes the validation steps in the 
development of CSF GAP-43 ELISA. 
 
4.3 Materials and methods 
4.3.1 The construction of GAP-43 recombinant protein 
 
All reagents used for the expression of GAP-43, including the baculovirus 
expression system and cell culture reagents were from Invitrogen (Paisley, UK) 
unless otherwise stated. 
 
The amino acid sequence for GAP-43 (UniProt #P17677) is illustrated in Figure 
4-1. Its membrane localisation is primarily due to a short amino terminal 
sequence comprising of the first ten amino acids of the N-terminus. Cysteines 3 
and 4 are crucial for the membrane association 213; 214. Therefore, when 
producing the soluble recombinant fusion GAP-43 protein we omitted the 
membrane binding area and used only amino acids 11 – 238 (Val – Ala) of 
GAP-43 to allow for its secretion during the expression phase of protein 
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production. The final construct generated encodes 287 amino acids long 
sequence which also contains an IL-2 signal peptide sequence at the N-
terminus and a linker sequence plus V5 epitope and polyhistidine tag (V5-His 
tag) at the C-terminus (Figure 4-2, 4-3). 
 
        10         20         30         40         50         60  
MLCCMRRTKQ VEKNDDDQKI EQDGIKPEDK AHKAATKIQA SFRGHITRKK LKGEKKDDVQ  
 
        70         80         90        100        110        120  
AAEAEANKKD EAPVADGVEK KGEGTTTAEA APATGSKPDE PGKAGETPSE EKKGEGDAAT  
 
       130        140        150        160        170        180  
EQAAPQAPAS SEEKAGSAET ESATKASTDN SPSSKAEDAP AKEEPKQADV PAAVTAAAAT  
 
       190        200        210        220        230  
TPAAEDAAAK ATAQPPTETG ESSQAEENIE AVDETKPKES ARQDEGKEEE PEADQEHA 
 
 
Figure 4-1 The amino acid sequence for GAP-43. We used the mRNA transcript ‘GAP-43, 
Accession no. NM_002045’ to generate this protein. 
 
 
M Y R M Q L L S C I A L S L A L V T N S V E K N D D D Q K I E Q D G I 
K P E D K A H K A A T K I Q A S F R G H I T R K K L K G E K K D D V Q 
A A E A E A N K K D E A P V A D G V E K K G E G T T T A E A A P A T G 
S K P D E P G K A G E T P S E E K K G E G D A A T E Q A A P Q A P A S 
S E E K A G S A E T E S A T K A S T D N S P S S K A E D A P A K E E P 
K Q A D V P A A V T A A A A T T P A A E D A A A K A T A Q P P T E T G 
E S S Q A E E N I E A V D E T K P K E S A R Q D E G K E E E P E A D Q 
E H A I Q H S G G R S S L E G P R F E G K P I P N P L L G L D S T R T 
G H H H H H H 
 
Figure 4-2 The amino acid sequence of the recombinant GAP-43 protein. The IL-2ss-
GAP43-V5-poly(His) construct has an IL-2 secretion sequence at the N-terminus (in pink) and a 
linker sequence plus a V5-poly(His) tag at the C-terminus (in blue). The GAP-43 sequence is in 
black.  
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Figure 4-3 Attributes of the recombinant GAP-43 protein. A) native protein and B) 
engineered IL2ss-GAP43-V5-poly(His) tag protein. The engineered protein is 287 amino acids 
long compared to the native 238 amino acid GAP-43 and lacks the N-terminus membrane-
binding region (amino acids 1-10) which has been replaced by the 20 amino acid IL-2ss at the 
N-terminus and the 39 amino acid linker sequence plus V5-His tag at the C-terminus. 
Palmitoylation of Cys 3, 4 is required for plasma membrane association. The calmodulin binding 
domain (amino acids 43-58) and several phosporylation sites, including serine 41 remain 
unchanged. Phosphorylation at serine 41 by protein kinase C (PKC) regulates calmodulin 
binding and modulates the ability of GAP-43 to facilitate neuronal growth. M-calpain mediated 
GAP-43 proteolysis creates a truncated GAP-43, which is believed to activate Go-mediated 
growth cone collapse. 
 
The IL-2 signal peptide improves the level of secretion of recombinant proteins 
in the baculovirus expression system by directing the GAP-43 propeptide to the 
endoplasmic reticulum and through the secretory pathway 215. GAP-43 is 
expressed as a fusion to the V5-His tag via a peptide linker to facilitate 
immunodetection and protein purification. The recombinant GAP-43 protein was 
designed by Dr Nasim Yousaf at the Bone and Joint Research Unit, Barts and 
The London, Queen Mary’s School of Medicine and Dentistry, London. 
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4.3.2 Experimental outline of the baculovirus expression system 
 
The figure 4-4 below illustrates the steps required to express the GAP-43 gene 
using the baculovirus expression system. 
 
 
 
Figure 4-4 The flow chart demonstrates the experimental outline of the steps used to 
express GAP-43 gene using pcDNA6B and pFastBacI vectors and generate recombinant 
baculovirus used in protein expression. Initially GAP-43 gene was cloned into pcDNA6B 
vector and the construct was amplified by PCR. The PCR product was recovered and 
subcloned into the pFastBacI vector. The final recombinant vector was used to transform 
recipient E.coli cells and the plasmid DNA was harvested. The final steps of transfection of 
pcDNA6B construct 
Recombinant IL-2-GAP43-V5-
His/pcDNA6B construct 
Recombinant IL-2-GAP43-V5-
His/pFastBac1 construct 
E.coli colonies with 
recombinant GAP-43 plasmid 
Recombinant GAP-43 plasmid 
DNA 
P1 recombinant baculovirus 
stock (>106 pfu/ml) 
P2, P3 recombinant 
baculovirus stocks (≥107 
pfu/ml) 
Protein Expression 
Transfect insect cells 
Infect Sf9 cells to amplify 
virus 
Titre and infect HiFive cells 
Grow culture and isolate 
recombinant plasmid DNA 
Transform into DH10Bac 
cells 
Amplify and subclone into 
pFastBacI 
Clone GAP-43 
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GAP-43 recombinant DNA into insect cells lead to the generation of baculovirus particles that 
were scaled up in successive rounds of infection and later used for protein expression. 
 
4.3.2.1 Recombinant GAP-43 protein (IL-2-GAP43-V5-His) construct 
 
The complementary DNA encoding amino acids 11-238 of GAP-43 was cloned 
in-frame downstream of the secretion signal from IL-2 gene, which had 
previously been subcloned into mammalian pcDNA6/V5-HisB vector (Invitrogen, 
Figure 4-5). The cloning strategy allowed the generation of V5 and 6xHis tags at 
the C-terminus of the GAP-43 protein (Figure 4-3), and these tags were used 
for immunodetection and purification, respectively. Using this construct as a 
template, the IL-2ss-GAP43-V5-His was amplified by PCR using the forward 
primer (5’- ACGAATTCGGTTGAAAAAAATGATGACGACC –3’) and the reverse 
primer (5’- GGCATGTTCTTGGTCAGCCTC –3’). The PCR product was then 
recovered from the PCR reaction by ethanol precipitation, digested with 
BamHI/PmeI and subcloned in frame into the baculovirus vector pFastBac1 
(Invitrogen, Figure 4-6) cut with BamHI/StuI. The final construct generated 
encodes IL-2ss-GAP43-V5-His. The IL-2ss-GAP43-V5-His/pFastBacI construct 
was transformed into Competent DH10Bac cells (Escherichia coli) for 
amplification. Subsequently, the recombinant plasmid was prepared from this 
and later transfected into Sf9 insect cells (Spodoptera frugiperda) to produce 
the first P1 baculovirus stock.  
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Figure 4-5 The restriction enzyme and genetic map of the commercial vector pcDNA6/V5-
His B (Invitrogen). The coding sequences of the GAP-43 gene were cloned immediately 
downstream of the secretion signal IL-2ss. The vector was digested at BamHI/PmeI with the 
appropriate enzymes. 
 
 
105 
 
 
Figure 4-6 The restriction enzyme and genetic map of the commercial vector pFastBac1 
(Invitrogen). The coding sequence of IL-2ss-GAP43-V5-His was cloned into pFastBac1 
digested at BamHI/StuI with the appropriate enzymes. 
 
 
At all stages of cloning, the plasmids were analyzed by restriction enzyme 
digestion and by sequencing both DNA strands using the ABI Prism BigDye 
terminator sequencing kit and an ABI automated DNA analyzer at the Genome 
Centre of The William Harvey Research Institute. The analyses of both the 
nucleotide and the putative translated amino acid sequences were performed 
by DNA and protein databases (www.ncbi.nlm.nih.gov and 
http://us.expasy.org).  
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4.3.2.2 Isolating P1, P2 and P3 viral stocks 
 
The Sf9 cell line (S frugiperda) was maintained in Sf-900 II SFM media (Gibco) 
supplemented with 2mM of L-glutamine, 100 U/ml of penicillin and 100 μg/ml of 
streptomycin. For transfection, Sf9 cells (9 x 105) were seeded in each 6-well 
(35 mm) tissue culture plate with 2 ml of growth medium and transfection 
carried out with 1 μg of GAP-43 recombinant DNA. The cells were incubated in 
a 27oC humidified incubator for approximately 72 hours until there were signs of 
viral infection (a 25-50% increase in cell diameter and increase in size of cell 
nuclei in the first 24 hours, followed by cessation of cell growth and signs of viral 
budding and granular appearance to the cells in the late 24-72 hours). The 
media were then collected to harvest the virus and centrifuged at 500 x g for 5 
min at room temperature to remove cell debris. The resultant clarified 
supernatant was passed through a 0.45 μm filter (Sartorius) to remove further 
particulate material from the concentrated P1 GAP-43 viral stock. Subsequently 
using the P1 viral stock, higher titre P2 and P3 stocks were generated. The 
numbers of Sf9 cells required for the transfections were calculated beforehand 
and the cells expanded accordingly. They had to have greater than 95% viability 
and to be growing in the logarithmic phase with a density of 1.5-2.5 x 106 
cells/ml before proceeding to transfection. 2 x 106 Sf9 cells/small flask 
(Sartorius) were plated in a monolayer culture transfected with 0.4 ml P1 viral 
stock and incubating cells at 27oC for 72 h or until signs of viral infection, to 
generate the P2 viral stock. Using 200 μl of the P2 stock, I transfected 8 x 106 
Sf9 cells/medium flask (Sartorius) to generate an even higher-titre P3 stock. 
The titre of the stocks was determined using the plaque assay (see performing 
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a viral plaque assay). For long-term storage, aliquots of baculovirus stocks were 
stored in cryotubes at -80oC.  
 
4.3.2.3 Viral Plaque Assay 
 
The titre of the P3 baculovirus stock was calculated in plaque-forming units 
(pfu) per millilitre in the plaque assay. To perform the plaque assay, eight-log 
serial dilution (10-3 – 10-8) of the virus stock were prepared in SF-900 II SFM 
medium and 1 mL aliquots of appropriate virus dilution were inoculated onto 
susceptible Sf9 cell monolayers (1 x 106 cells) in a 6-well plate and gently 
rocked to evenly distribute the virus. After an incubation period of 1 hour at 
room temperature, the virus stock and medium was removed and replaced with 
neutral red agarose overlay (1 mg/ml neutral red solution in Sf-900 (1.3x) 
plaquing medium (Invitrogen) combined with 4% agarose (BD BaculoGoldTM) 
and allowed to set. The 6-well plate was then incubated in 27oC humidified 
incubator for 7 – 10 days until plaques (a circular area of infected cells) were 
visible. To facilitate counting 0.5 mL of neutral red solution (1 mg/ml neutral red 
solution in cell-culture grade, distilled water) was added to each well and 
incubated for 1 – 2 hours at room temperature. After removing excess stain, 
plaques appeared as near clear spots in the gel contrasted against red 
background. 
 
The titre was calculated as follows: 
 
Titre (pfu/ml) = no. of plaques x dilution factor x                1 
                                                                              ml of inoculum/well 
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P3 baculovirus stock titre was 2 x 107 pfu/ml. 
 
4.3.2.4 Expression of recombinant GAP-43 protein in insect cells 
 
The Trichoplusia ni High FiveTM cell line (20 x 106 cells/large flask) maintained 
in Express 5 SFM media (Gibco) supplemented with 2 mM of L-glutamine, and 
100 U/ml of streptomycin and 100 μg/ml of streptomycin was transfected with 
the P3 recombinant 250 μl of baculovirus stock. The cells were incubated in a 
27oC humidified incubator and the transfected cell supernatants harvested at 72 
hours post-infection. The level of protein expression (multiplicity of infection 
(MOI) and time course of infection) was optimised and protein expression was 
examined in western blots. Procedure was scaled up from one culture flask to 
six in order to increase the final GAP-43 protein yield. 
 
Recombinant protein supernatants were centrifuged at 500 x g, filtered to 
remove cell debris and loaded into dialysis tube with a 10k molecular weight 
cut-off before dialysing in 1x PBS, pH 7.4 (Sigma). Samples were then stored at 
-80oC awaiting purification. 
 
4.3.2.5 Isolation of recombinant GAP-43 protein 
 
Recombinant GAP-43 (His) protein was purified using a prepacked Ni2+-
Sepharose HiTrap Chelating HP column (1 ml, GE Healthcare, #71-5027-68 
AH) according to manufacturer guidelines with slight modifications to achieve 
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higher purity. Distilled water and analytical grade chemicals were used. 
Solutions were filtered through 0.22 μm filters (Sartorius).  
 
Briefly, the purification procedure (performed at +4oC) consisted of the following 
steps. Firstly, the HiTrap column was washed with 5 ml of distilled water, 
followed by equilibration with 10 ml of 1x native binding buffer (see Appendix for 
chapter 4). The GAP-43 containing samples were then pooled and applied to 
the column at a flow rate of 1-4 ml/min manually using a 10 ml syringe. Some of 
the flow-through fraction was saved for later analysis. The column was then 
washed with 10 ml of native wash buffer with 20 mM imidazole (see Appendix 
for Chapter 4) to minimise the binding of host cell proteins and some of the 
wash fraction was collected for analysis. Finally, elution of GAP-43 was carried 
out using 5 ml of native elution buffer with 250 mM imidazole (see Appendix for 
Chapter 4) and the eluted fractions ware collected in small fractions of 0.5 ml to 
avoid dilution of the protein. These were then dialysed against 5 L of 1x PBS, 
pH 7.4 to remove trace amounts of imidazole. The purity of the final 
recombinant GAP-43 fusion protein thus obtained was assessed by western 
blotting and examined further by mass spectrometry (Dr Wendy Heywood, 
Biochemistry group, Institute of Child Health). 
 
Purification procedure under denaturing conditions was also compared with the 
addition of urea to the binding, wash and elution buffers (see Appendix for 
Chapter 4). Protein concentrations were determined by using Bio-Rad 
(Bradford) protein assay. Briefly, 25 μl of Reagent A was loaded onto wells in a 
Nunc Maxisorp microtitre plate, followed by standards (0.063 mg/ml, 0.125 
mg/ml, 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml and 2 mg/l) and sample at 10 μl in each 
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well. Reagent B was loaded at 200 μl per well. The plate was then left to stand 
at room temperature for 10 minutes with gentle agitation and read at 750 nm 
using FLUOstar Omega (BMG Labtech). The standards were plotted and the 
total protein value was calculated from the standards.  
 
4.3.2.6 Western blot analysis 
 
Specificity of purified recombinant GAP-43 protein was analysed by western 
blot analysis. 6.5 μl protein sample was solubilised in 2.5 μl NuPAGE LDS 
buffer (4x) and 1μl NuPAGE sample reducing agent (10x), boiled for 15 min and 
separated on NuPage 4-12% Bis-Tris,10 well, 1.0 mm precast gel (Invitrogen) 
alongside a 10 to 191 kDa molecular weight marker. Immunoreactivity labelling 
was carried out with anti-GAP-43 primary antibody 1/1000 dilution (NM2, 
#MN1090, Thermo Scientific), detected using anti-mouse HRP-conjugated 
secondary antibody 1/2000 dilution (#P0260, Dako) and visualised with 
enhanced chemiluminescence (Thermo Scientific). A more detailed western blot 
methodology can be found in Chapter 2. 
 
4.3.3 Proteomic analysis of recombinant GAP-43 protein 
4.3.3.1 In-gel tryptic digestion of recombinant GAP-43 protein from 1D 
polyacrylamide gel 
 
Coomassie blue stained bands at approximately 51 and 97 kDa of the GAP-43 
fusion protein run on a 1D polyacrylamide gel were cut out for identification by 
mass-spectrometry. The excised gel pieces were placed into sialinised 
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eppendorfs that have been previously washed with 200 μl of methanol to 
remove any contaminants. The following portion of the work was performed by 
Dr Wendy Heywood. 
 
The coomassie stained gel bands were placed into de-staining solution (300 μl 
of 50% methanol containing 0.1% acetic acid) incubated at 37oC to remove as 
much of the coomassie as possible. The gel pieces were then washed with 200 
μl of 50 mM ammonium bicarbonate buffer (pH 7.8) to remove any residual 
buffers. 500 μl of LC-MS grade acetonitrile was added to the gel pieces and 
rotated for 30 min to dehydrate them, and transferred into a centrifugal 
evaporator until completely dry (approximately 30 min). Any disulphide bridges 
that have reformed were re-broken using 10 mM DTE (Cleland’s reagent) in 50 
mM ammonium bicarbonate buffer, pH 7.8, incubated at 37oC for 1 hr. Excess 
DTE solution was discarded and the gel pieces were again washed in 
ammonium bicarbonate buffer. Carboamidomethylation of the proteins was 
performed by adding 300 μl of 100 mM ammonium bicarbonate containing 55 
mM iodoacetamide allowing the reaction to proceed in the dark for 45 min at 
room temperature. The supernatants were discarded and the gels were washed 
in ammonium bicarbonate buffer three times. Prior to in-gel digestion, gel pieces 
were dehydrated using methods outlined above. 60 μl of of 12.5 ng/μl of 
sequencing grade trypsin solution in 50 mM ammonium bicarbonate buffer, pH 
7.8 were added to cover the gel pieces and incubated for 12 h or overnight at 
37oC in a waterbath. After digestion, the peptides from the gels were extracted 
3 x 20 min each with: 1) 200 μl of 1% formic acid to collect the more hydrophilic 
peptides, 2) in a new, silanised eppendorf 300 μl of 50% ACN/1% formic acid to 
collect most of the tryptic peptides, and 3) a further 300 μl of 50% ACN/1% 
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formic acid. To the collected supernatants 200 μl of 1% formic acid was added, 
vortexed and freeze-dried. 
 
4.3.3.2 LC-MS/MS (ESI-QTOF MS) analysis 
 
The peptides in each digest were analysed using a nanoAcquity HPLC and Q-
TOF Premier mass spectrometer (Waters Corporation, Manchester, UK). In 
brief, peptides were trapped and desalted using a Symmetry C18 5 μm, 5mm x 
300 μm precolumn in 0.1% formic acid at a flow rate of 4 μl/min for a total of 4 
min before elution and separation on a 15 cm x 75 μm reverse phase analytical 
column using a linear gradient of 3-40% acetonitrile [0.1% formic acid] over a 
period of 90 min at 300 nl/min. Peptides were analysed in a positive mode using 
Q-TOF Premier mass spectrometer and was operated in v-mode with a typical 
resolving power of 10,000 FWHM. Prior to analysis, [glu1]-fibrinopeptide B 
fragments, a mass calibrant was used to calibrate the TOF analyser using 
collision energy of 25 V and over the mass range 50-2000 m/z. Mass spectra 
were acquired in a data independent and alternating, low and high collision 
energy mode. Each low/high acquisition was 1.5 s with 0.1 s interscan delay. 
The collision energy used was performed for low energy data collections at 4 V 
and varied at 15-40 V ramp for high energy collisions. 
 
The raw Q-TOF MS data was processed using the ProteinLynx Global Server 
ver 2.4. Database searching was with UniProt/Swiss-Prot databases to which 
the recombinant GAP-43 sequence was added manually. Protein identification 
form the low/high collision spectra for each sample was processed using a 
hierarchical approach where more than three fragment ions per peptide, seven 
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fragment ions per protein and more than two peptides per protein had to be 
matched.  
 
4.3.4  Quantitation of GAP-43 
4.3.4.1 Patients 
 
Cell-free CSF samples and paired serum from 172 patients (age range 17 to 81 
years; 69 males, Table 4-1) from the CSF laboratory archives approved by the 
local ethics committee was utilised for the detection of GAP-43. The sample age 
range was from 2009 – 2010 and stored at -20oC (analysis was performed in 
2010). Assays were performed blind to clinical data and their diagnoses are 
detailed below. Control CSF consisted of headache cases without features of 
raised CSF pressure and back pain. Full diagnostic work-up in this group failed 
to detect any neurological cause for their symptoms. 
 
Further analysis of CSF GAP-43 was performed in 32 patients with secondary 
progressive MS (SPMS) participating in the Lamotrigine clinical trial described 
earlier (see Chapter 2). Their mean age was 52 and had steady progression of 
the disorder since its onset as evidenced by disability scores (EDSS) ranging 
from 4 to 8. 
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Diagnosis N Gender 
(M:F) 
Age 
(years) 
Dementia 26 9:17 60 (19-80) 
BIH 22 21:1 30 (17-54) 
Movement disorders 16 7:9 57 (29-71) 
MS 38 21:17 44 (17-76) 
Neuropathy 24 5:19 50 (17-81) 
CNS infections 23 11:12 44 (29-74) 
MND 10 6:4 54 (35-68) 
Neurological 
controls 
13 4:9 53 (49-60) 
 
Table 4-1 Clinical characteristics of patients. Age values are expressed as means (ranges). 
N = number of individuals; M = male; F = female; BIH = Benign Intracranial Hypertension; MS = 
Multiple Sclerosis; MND = Motorneurone Disease. 
 
4.3.4.2 Antibodies and standard curve 
 
Monoclonal anti-GAP-43 primary antibodies, clones NM2 (#MN1090) and 31 
(#612262) were from Thermo Scientific and BD Transduction Laboratories, 
respectively. Secondary polyclonal antibody was a rabbit anti-GAP-43 antibody 
from GeneTex (#GTX 30199), whilst the tertiary antibody was swine anti-rabbit-
HRP (#P0217) from Dako.  
 
Newly purified recombinant GAP-43 protein was double diluted in 2% semi-
skimmed milk (Marvel)/1 x PBS (Sigma), pH 7.4, from a top standard measuring 
1.6 mean OD in duplicates, corresponding to 145 ng/ml of GAP-43 (refer to 
4.3.2.5 for determination of recombinant protein concentration). 
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4.3.4.3 Enzyme-linked immunosorbent assay for GAP-43 
 
Analyses of GAP-43 levels in CSF samples were carried out in duplicate wells 
by ELISA. Microwells of polystyrene Nunc-MaxiSorpTM were coated overnight at 
+4oC with either NM2 antibody at 2 μg/ml or 31 antibody at 1.25 μg/ml in PBS 
(NaCl 0.138 M; KCl 0.0027 M), pH 7.4 (Sigma). Plates were washed with 200 μl 
of 1M PBS and incubated with 2% semi-skimmed milk (Marvel)/PBS for 1 hour 
at room temperature to block non-specific binding. The wells were emptied and 
again rinsed with 200 μl of PBS. Test CSF, recombinant standard and controls 
at 50 μl in 50 μl of 2% semi-skimmed milk/PBS were incubated for 1 hour at 
room temperature on a plate shaker. After being rinsed with PBS containing 
0.05% Tween 20 (Sigma) five times, the plate was incubated with polyclonal 
rabbit anti-GAP-43 (2 μg/ml in 2% semi-skimmed milk/PBS) for 2 hours with 
shaking at room temperature.  After washing as above, swine anti-rabbit-HRP 
was diluted 1/2000 in 2% semi-skimmed milk/PBS was added to the plate and 
incubated for 2 hours at room temperature with shaking. The wash steps were 
repeated, followed by a rinse with PBS only. 100 μl of 3, 3’, 5, 5’-
Tetramethylbenzidine (Sigma) chromogenic substrate was added to the wells 
and the reaction was allowed to proceed for 10 min in the dark at room 
temperature. The reaction was stopped using 50 μl 1 M hydrochloric acid and 
absorbance measured at 492 nm with wavelength correction at 540 nm in 
FLUOStar Omega plate reader (BMG Labtech). Sample values were expressed 
as ng/ml calculated from the standard curve of GAP-43 antigen. 
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4.3.4.4 Calculations of blood-brain barrier (BBB) function and IgG 
synthesis 
 
Quantitative determination of serum and CSF albumin, and serum and CSF IgG 
was performed by nephelometry, using the BN ProSpec analyser (Siemens). 
The CSF/serum albumin (ALB) ratio was calculated as [ALBCSF (mg/l)/ALBSERUM 
(mg/l) x 100%] and utilised as an indicator of BBB function. IgG index was 
calculated as [(IgGCSF (mg/l)/IgGSERUM (mg/l)) x (ALBSERUM (mg/l)/ALBCSF (mg/l))] 
and utilised as an indicator of intrathecal IgG synthesis. 
 
4.3.4.5 Statistical analysis 
 
All analysis was performed using SPSS version 16. Comparisons between the 
different diagnostic categories were performed using ANOVA after establishing 
normality using the one-sample Kolmogrov-Smirnov test. The level of statistical 
significance was set at 0.05. Multiple comparisons were adjusted using 
Bonferroni correction. The effects of age and gender on GAP-43 concentrations 
were tested using regression analysis with age as a covariate and gender as a 
factor. Spearman-rank correlation was performed between CSF GAP-43, 
albumin quotient and IgG index to assess whether GAP-43 values rose with 
blood-brain barrier dysfunction or intrathecal IgG synthesis. Relative association 
of CSF GAP-43 concentrations to clinical measures of disease progression in 
patients with SPMS was tested by linear regression with CSF GAP-43 as the 
dependent variable. Log transformation was preformed because of the skewed 
distribution. 
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4.3.5 Western blot analysis of endogenous antibodies against GAP-
43 in serum/CSF 
 
A random selection of serum/CSF samples from MS subjects were tested for 
reactivity against recombinant GAP-43 by western immunoblotting looking for 
endogenous antibodies to GAP-43. A similar method to that described in 
Chapter 2.5.5 was used for this purpose; 20 μg of denatured purified 
recombinant GAP-43 protein was run on NuPage 4-12% Bis-Tris 2D well 
precast gel (Invitrogen), and polyclonal rabbit anti-GAP-43 (GeneTex, #GTX 
30199) at a dilution of 1/500 was used to probe the positive control and 
detected using 1 in 1000 dilution of anti-rabbit IgG/HRP (Dako, #P0217), whilst 
anti-human IgG/HRP (Dako, #P0214) at a dilution of 1/1000 was used for the 
MS samples. 
 
4.4 Results 
4.4.1 Recombinant GAP-43 protein 
4.4.1.1 Secretion of GAP-43 protein 
 
Supernatants from the baculovirus infections were resolved by SDS-PAGE and 
immunodetected with anti-V5 antibodies. Figure 4-7, lanes 1 – 3, shows the 
protein profile of recombinant GAP-43 at differing sample volumes purified 
under native conditions, whilst lanes 4 – 6 shows the protein staining pattern 
purified under denaturing conditions (using urea). Both procedures show the 
same characteristics for GAP-43; a major band at Mr 51 kDa and a minor band 
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at Mr 97 kDa were identified, indicating that the two methods of purification did 
not differ. Subsequent in-gel trypsin digestion of Coomasie stained protein 
bands followed by LC-MS/MS identified them as GAP-43 with 60 – 72% peptide 
coverage against the modified GAP-43 sequence (Figure 4-8). These may 
represent post-translational modifications that occur during production and 
secretion of the fusion protein or represent protein dimerisation.  
 
 
 
 
Figure 4-7 Western blot of GAP-43 fusion protein purified under native (lanes 1-3) and 
denaturing (lanes 4-6) purification conditions. The blot was probed using anti-V5 antibody. 
Different volumes of the protein were run (lanes 1+4=50 μl, 2+5=100 μl, 3+6 =150 μl) 
demonstrating that both native and urea-purified GAP-43 do not differ significantly. SDS-PAGE 
was run in denaturing conditions. 
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Mr 51 kDa: 
 
 
Entry Description 
PLGS 
Score 
Peptides 
Coverage 
(%) 
REC_GAP43 Neuromodulin GAP 43 9587 52 72 
      
Mr 97 kDa: 
 
 
Entry Description 
PLGS 
Score 
Peptides 
Coverage 
(%) 
REC_GAP43 Neuromodulin GAP 43 6291 38 60 
     Figure 4-8 Peptide coverage maps of the (A) 51 kDa and (B) 97 kDa recombinant GAP-43 
protein bands. Regions of the protein sequence that matched to a peptide are highlighted in 
blue. The arrow marks the start of the GAP-43 protein, but peptide matches are evident also for 
the N-terminal signalling protein (*) demonstrating variation in cloning in the Baculovirus system. 
Percentage sequence coverage is included for both bands as well as their PLGS scores. The 
PLGS score is a statistical measure of accuracy of assignation and is calculated by Protein 
GAP-43 
GAP-43 
A 
B 
* 
* 
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Lynx Global Server (Waters) from all available mass spectrometry data, a higher score implies a 
greater confidence of protein identity.  
 
 
 
 
 
 
Figure 4-9 Coomassie blue stained gel (A) and western blot (B) probed using anti-GAP-43 
NM2 antibody of recombinant GAP-43.  HiTrap column sequential elutes are labelled E1-E9. 
The gel and the corresponding blot demonstrate a predominant band at <60 kDa and a lesser 
one at <100kDa. Adding imidazole to the wash improved the purity of GAP-43 obtained 
(compare E3 pre-imidazole elute in the right hand corner of the gel with E3 post-imidazole in the 
main gel). 
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4.4.1.2 Isolation of recombinant GAP-43 protein 
 
Figure 4.9 shows the elution of the purified recombinant GAP-43 protein from a 
HiTrap 1 ml column. Adding imidazole to the wash yielded a highly purified 
product (see E3 in the far right corner of the coomassie gel pre-imidazole). 
Elutes 3, 4 and 5 were selected for use in ELISA development, protein 
concentration of 0.45 mg/ml. 
 
4.4.2 GAP-43 immunoassay performance characteristics 
 
4.4.2.1 Monoclonal 31 versus NM2 GAP-43 ELISA 
 
Agreement between CSF GAP-43 levels measured using 31 and NM2 
antibodies was calculated across the assay working range (n=30) using the 
Bland-Altman plot (where x-axis is the mean of the two measurements of GAP-
43 and y-axis is the difference between the two values, Figure 4.10) 216. The 
correlation between the two methods was r2 = 0.88, 95% limits of agreement of 
+32.2 ng/ml (mean +2SD) and -18.8 ng/ml (mean -2SD) with only a few 
readings outside this range. The 31 assay over-estimated GAP-43 values 
compared to the NM2 assay. Based on this and a signal-to-noise ratio of 1.6 
OD using the NM2 assay compared to 31 assay of 1.3. OD, it was decided to 
continue using the NM2 assay for future work. 
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Figure 4-10 Correlation of mean GAP-43 concentrations measured using GAP-43-31 and 
GAP-43-NM2 (A) and Bland-Altman plot of the two methods (B). The Bland-Altman plot 
calculates the mean difference between the two methods of measurement (the ‘bias’), and 95% 
limits of agreement (2 SD) to show how well the two methods of measurement agree. GAP-43-
31 method reads slightly higher creating a bias of 6.7 ng/ml and limits of agreement of -18.2 
(mean-2SD) and 32.2 (mean+2SD) ng/ml (C). The bias between the two assays is 
demonstrated graphically in the histogram but majority of the readings read with zero bias. 
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4.4.2.2 Assay sensitivity and precision 
 
The limit of sensitivity of the NM2 GAP-43 ELISA was calculated by assaying 
the zero standard repeatedly twenty times and taking the concentration 
corresponding to 2SD above the mean. The sensitivity of the assay was 4.1 
ng/ml. Within-run (intra-assay) precision was based on the mean and standard 
deviation of 5 replicates of the standard curve run in a single assay and 
expressed as the percentage coefficient of variation (CV%), whilst between run 
(inter-assay) precision was based on the mean and standard deviation of 5 
replicates of the standard curve from run to run and day to day and expressed 
as the percentage CV (Table 4-2). The quality control data over twenty days 
plotted on to the Levey-Jennings plot demonstrates that the ELISA is working 
well (Figure 4.11). 
 
GAP-43 concentration n Intra-assay Inter-assay 
(ng/ml)  SD CV SD CV 
4.5 5 0.10 2.1% 0.09 2.1% 
9.1 5 0.39 4.3% 0.31 3.4% 
18.1 5 0.57 3.2% 0.36 2.0% 
36.3 5 2.34 6.5% 1.58 4.4% 
72.5 5 5.55 7.7% 3.25 4.5% 
145 5 7.53 5.2% 5.56 3.8% 
 
Table 4-2 Precision profile describing the GAP-43 assay performance across the assay 
range. The amount of error (standard deviation [SD], % Coefficient of variation [CV]) at specific 
concentration values is shown. 
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Figure 4-11 Levey-Jennings Plot with the quality control data of GAP-43 ELISA plotted 
over 20 days. Majority of the readings are within the upper and lower limits of two standard 
deviations from the mean. 
 
 
4.4.2.3 Parallelism and recovery 
 
The parallelism of the assay was determined by assaying four CSF of similar 
concentration as the top standard diluted to the zero standard, demonstrating 
that the dilutions lie parallel to the standard curve (Figure 4.12). Recovery 
studies were performed using four samples spiked with four different 
concentrations of analyte (1:1 dilution factor) and the percentage recovery 
calculated. The average recovery across four pairs of CSF samples was 
104.5% (range 80.8 – 114%). Whilst mean recovery in sera were 103.7% 
(range 96.9 – 108.9%). 
 
 
-4 
-3 
-2 
-1 
0 
1 
2 
3 
4 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
SD
 
Day 
 
 
125 
 
 
 
Figure 4-12 Comparison of recombinant GAP-43 standard and natural GAP-43 in CSF 
sample from a patient tested in dilutions. Parallelism between standard and natural GAP-43 
was demonstrated in this comparison. 
 
4.4.2.4 GAP-43 stability as determined by freeze-thaw cycles and 
temperature adjustments 
 
Triplicate aliquots of CSF were frozen at -80oC and then taken through five 
repeated freeze-thaw cycles, and also stored at room temperature, +4oC, and -
20oC for a seven-day period. Analysis shows that CSF GAP-43 values were not 
strongly influenced by these adjustments (Figure 4-13). 
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Figure 4-13 GAP-43 stability (freeze/thaw cycles, A) and storage (B). This demonstrates 
that the stability of GAP-43 is not influenced by five freeze/thaw cycles or storage at different 
temperatures over seven days. 
 
 
 
4.4.3 GAP-43 in neurological disorders determined by the NM2 GAP-
43 assay 
 
The mean GAP-43 values ± SD (ng/ml) were 303 ± 388 (dementia), 287 ± 295 
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(MS), 337 ± 283 (neuropathy), 331 ± 289 (CNS infections), 174 ± 128 (MND), 
and 522 ± 203 (neurological controls – headache subjects) (Figure 4-14). Mean 
CSF GAP-43 levels were significantly lower in movement disorders (p=0.001), 
MS (p<0.001), MND (p=0.03) than in neurological controls. The high outlying 
values noted in dementia, BIH and neuropathy were not uniquely different from 
the rest of their group with regard to their diagnosis, except in the CNS 
disorders where the highest GAP-43 level by far was found in a case of 
staphylococcus aureus meningitis (CSF GAP-43 of 1013 ng/ml) and cases of 
TB meningitis (CSF GAP-43 levels 632 to 996 ng/ml).  
 
There were no significant correlations between CSF GAP-43 levels, and 
albumin quotient (mean 0.83 mg/l (0.15 – 5.51 mg/l); r=-0.11, p=0.47) and IgG 
index (mean 0.59 mg/l (0.30 – 1.65 mg/l); r=-0.02, p=0.88). Per milliliter GAP-43 
concentrations were approximately ten times more in the CSF than in paired 
serum samples (Figure 4-15). Moreover, GAP-43 concentrations in CSF were 
not significantly associated with GAP-43 in serum (r=0.17, p=0.18). Linear 
regression analysis revealed that CSF GAP-43 levels were not associated with 
either age (p=0.83) or gender (p=0.34). 
 
Having established that CSF GAP-43 levels were low in patients with MS, a 
sub-group analysis was performed between the clinical MS subtypes. Mean 
GAP-43 ± SD were 168 ± 122 ng/ml (clinically isolated syndromes, CIS), 193 ± 
154 ng/ml (relapsing-remitting MS, RRMS), 116 ±112 ng/ml (secondary 
progressive MS, SPMS), and 142 ± 80 ng/ml (primary progressive MS, PPMS), 
without significant differences on statistical analysis (p=1.00, 1-ANOVA). I also 
examined whether CSF GAP-43 levels could reflect the degree of disability. To 
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this purpose, GAP-43 was assayed in SPMS patients with EDSS scores 
ranging from 4 to 8 (mean EDSS ± SD of 6.0 ± 1.0), disease duration ± SD of 
22.1 ± 9.8 years, and duration of progression ± SD of 11 ± 6.1 years. CSF GAP-
43 concentrations were not significantly correlated with EDSS scores (r=-0.01, 
p=0.47), disease duration (r=-0.16, p=0.19) or duration of progression (r=-0.15, 
p=0.21). 
 
 
Figure 4-14 CSF GAP-43 in neurological controls versus neurological disorders The 
dementia cohort comprises 10 Alzheimer’s disease, 8 unspecified memory problems, 5 minimal 
cognitive impairment, 1 frontotemporal dementia, 1 semantic dementia, 1 vascular dementia. 
The movement disorders cohort comprises of 7 Parkinson’s disease, 5 progressive 
supranuclear palsy, 1 multisystem atrophy, 1 ballismus, 1 akinetic rigid syndrome, 1 involuntary 
movements. The multiple sclerosis (MS) cohort comprises 19 relapsing remitting MS, 7 clinically 
isolated syndrome, 7 primary progressive MS, 5 secondary progressive MS. The neuropathy 
cohort comprises of 7 peripheral neuropathy, 5 Guillain-Barre syndrome, 3 chronic inflammatory 
polyneuropathy, 2 motor neuropathy, 2 multifocal motor neuropathy, 1 mononeuritis multiplex, 1 
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ganglioneuropathy, 1 Charcot-Marie-Tooth disease, 1 small fibre neuropathy, 1 compressive 
neuropathy. CNS infections cohort comprises of 11 unspecified viral encephalitis, 5 tuberculous 
meningitis, 2 HIV, 1 Staphylococcus aureus meningitis, 1 zoster encephalitis, 1 HTLV-I, 1 
meningococcal meningitis, 1 neuroretinitis. GAP-43 levels were lower in movement disorders 
(P=0.001), MS (P<0.001), motorneurone disease (MND) (P=0.03) than in neurological controls 
(headache subjects).  
 
 
 
 
 
 
Figure 4-15 Comparison of GAP-43 concentrations in paired CSF and serum samples. 
GAP-43 concentrations were higher in CSF than in serum. 
 
 
 
 
 
130 
 
4.4.4 GAP-43 antigen-specific antibodies in serum/CSF 
 
Antibodies to GAP-43 were uncommon in the CSF, with only one weakly 
positive sample out of the 50 CSF samples tested (Figure 4-16). There were no 
GAP-43 antigen-specific antibodies identified in the serum samples tested. 
 
 
 
 
 
 
 
Figure 4-16 Western blots of GAP-43 antigen-specific antisera in MS CSF and controls. 
Weakly positive band was seen in lane 3 only (marked by *). Lane 1 and 7 includes the positive 
and negative controls, respectively. 
 
4.5 Discussion 
 
GAP-43, arguably one of the best characterised markers of growing, developing 
and regenerating neurones (see reviews by Benowitz et al. 35, Oestreicher et al. 
217 and Strittmatter et al. 218), is poorly understood when it comes to its 
neurogenic properties in the spinal fluid. As there are very few publications in 
the literature dedicated to this matter, it is very difficult, at present, to draw clear 
conclusions. Nonetheless, due to the inaccessibility of the human brain, the 
study of CSF proteins derived from the CNS, remains the next best alternative. 
In this chapter, I described the development of recombinant GAP-43 protein in 
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preparatory amounts to be able to be used in an ELISA system for directly 
quantifying CSF GAP-43 concentrations. Previous descriptions of GAP-43 
ELISA reported on relative amounts of GAP-43 concentrations using partially 
purified GAP-43 199; 212; 219; 220 as the standard, although more recently an assay 
using recombinant GAP-43 has been reported on, though there is no 
description of its production beyond that of personal communication 110. To the 
best of my knowledge, there is no readily available commercial source for 
recombinant GAP-43 protein at the time of writing. 
 
GAP-43’s first ten amino acids which include cysteines 3 and 4 that are crucial 
for its membrane binding properties and once processed binds tightly to the 
inner growth cone membrane 35. Therefore, for GAP-43 to be reliably secreted 
from an expression system this span of amino acids at the N-terminus of the 
protein would have to be removed, which we did. Altering the amino acid 
sequence affects the primary structure, which may lead to major conformational 
changes affecting the tertiary structure of a protein, thereby making their 
recognition with monoclonal antibodies by immunoassay or simple immunoblot 
methods difficult. A 20 amino acid signal peptide sequence from the IL-2 gene 
was introduced upstream of the GAP-43 sequence into the vector to ensure that 
the protein was secreted from the infected cells with greater efficiency. We 
assume the recombinant GAP-43 is processed and released from the insect 
cells along a similar secretory pathway to the one described in vertebrates 221. 
However, from the peptide sequence coverage (Figure 4-8) it is evident that 
part of the IL-2 signalling peptide has been coded into the finished recombinant 
protein, suggesting that there are subtle differences between insect cells and 
mammalian cells after all. 
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The recombinant GAP-43 proteins thus produced was immunodetected with 
GAP-43 antiserum and subjected to immunoblot analysis, revealing a major 
labelled protein at approximately Mr 50 kDa and a secondary Mr 97 kDa protein 
was also detected. GAP-43 is considered to migrate anomalously in SDS-
polyacrylamide gels with an apparent Mr of 43 – 53 kDa which might be related 
to microheterogeneity caused by posttranslational modifications 211; 222. In fact, 
the second protein is probably too large to represent a posttranslational 
modification or even a pre-GAP-43 polypeptide, and most likely represents a 
dimeric molecule. Direct determination of the peptide sequences from 
proteolytic fragments using mass spectrometry, corresponded to 60 – 70% of 
the GAP-43 amino acids and confirmed their identity as GAP-43. Recently, 
Zaharov et al. 223 demonstrated that it was possible for GAP-43 to oligomerise 
in the presence of the anionic detergent SDS. Normally SDS is considered to be 
a strong denaturant unfolding secondary and non-disulfide-linked tertiary protein 
structures, but at concentrations below or near critical micelle concentration, 
which is about 0.005 – 0.01% SDS, SDS induces maximum cross-linking of 
proteins into oligomers. The final SDS concentration in the NuPAGE MES 
running buffer used for electrophoresis in my experiments was between 0.005% 
and 0.025%, which is within this range. SDS binding to the positively charged 
N-terminal domain (residues 1-40) and effector domain (residues 39-55) of 
GAP-43 favours this interaction.  
 
The results of CSF GAP-43 determinations obtained from the ELISA 
demonstrated significantly lower mean concentrations of GAP-43 in the 
movement disorders, MS and MND categories compared to controls. Previous 
studies of CSF GAP-43 have noted similar reductions in concentrations in MS 
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patients and PD patients 110; 111, it was not possible to make direct comparisons 
as the assays worked in very different ranges (picograms as opposed to 
nanograms per millilitre). CSF GAP-43 has not been previously measured in 
MND patients, however its neuronal expression had been found to be increased 
in amyotrophic lateral sclerosis tissues 224. The biological basis for the drop in 
GAP-43 levels in these groups can only be speculated upon; however, it is 
plausible since GAP-43 is involved in neuronal outgrowth and synaptogenesis, 
increased utilisation of the protein during degeneration might explain the 
decreased levels observed in the CSF. Alternatively, the drop in levels may be 
the result of increased protein turnover with the breakdown and removal of 
damaged neurones, or reflect a reduction in the number of neurones in the CNS 
110; 111. These explanations are not universally encompassing, since they cannot 
explain why three patients from the AD category had very high levels in CSF 
GAP-43 compared to the rest. Coleman et al. 202 alludes to this heterogeneity in 
AD cases, stating that GAP-43 expression in AD could be differentiated on the 
basis of neurofibrillary tangle density with reduced messenger levels in high 
tangle density and vice versa. In immunoassays, the presence of naturally 
occurring antibodies to the analyte within samples through interference, may 
lead to falsely low results especially in the case of an autoimmune-mediated 
disorder such as MS, however we found this not to be case after analysing a 
series of MS samples for anti-GAP-43 antibodies by western blotting.  
 
The BIH, neuropathy and CNS infections (including the cases of TB meningitis) 
categories were not found to be significantly different from that of the control 
group, the spread of data points indicates a heterogeneous study group, 
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emphasising that clinical characteristics alone are not always sufficient for 
interpretation and more information is needed on pathological correlates.  
 
In MS, further subgroup analyses revealed no significant differences in CSF 
GAP-43 levels when comparing CIS to RRMS to SPMS to PPMS. Moreover, 
GAP-43 in SPMS patients did not correlate with the degree of disability as 
assessed by the EDSS score, or the duration of disease or disease 
progression.  The fact that majority of the subjects were scored at an EDSS of 
6.0 may be an obvious explanation for the lack of correlation, but does not 
explain the lack of correlation observed with the other two measures of overall 
disease activity. A relatively small number of subjects were included in this 
initial study, I would like to have included a larger cohort with an even spread of 
EDSS measurements, and this will form the basis of a future study. Teunissen 
et al. 111 in their study, observed only a tendency towards a negative correlation 
between GAP-43 levels and EDSS (r=0.30, P<0.1), but again no correlation 
with disease duration.  
 
Only one study has been performed on serum levels of GAP-43 and found to be 
below the sensitivity level of the assay 111. I was able to detect GAP-43 in serum 
samples using my assay with negligible matrix interference, although the 
recorded levels were ten times less than the corresponding CSF level. Levels 
did not correlate with the albumin quotient, an index of blood-brain barrier 
function or IgG index, a measure of intrathecal IgG synthesis, supporting the 
notion that CSF GAP-43 levels are independent of both blood-brain barrier 
impairment and immune stimulation. Moreover, results from the paired CSF-
serum samples indicate that variation of GAP-43 concentrations in CSF was not 
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correlated with serum GAP-43 concentrations, suggesting that they may 
originate from different sources. But, what is clear from these results is that 
GAP-43 is primarily derived from the CNS, and thus is essential to sample the 
CSF. I also noted no differences in CSF GAP-43 levels between age and 
gender groups, and adjustments based on age and gender are not anticipated. 
 
In summary, I have presented a novel method for the production of recombinant 
GAP-43 protein using the baculovirus expression system. There was some 
microheterogeneity upon SDS-electrophoresis, but the structure of GAP-43 
including the epitopes for GAP-43 antibodies is preserved, enabling its use as 
an antigen within an ELISA system. A new method for the quantitation of GAP-
43 concentrations by ELISA, including validation steps are outlined in this 
chapter. The ELISA has sufficient sensitivity to be able to detect GAP-43 in both 
the CSF and serum, although paired CSF/serum analysis point to GAP-43 
being exclusively CNS derived and do not vary as a function of serum GAP-43 
concentrations. Lastly, CSF GAP-43 analyses from this study supports earlier 
findings for a role of GAP-43 in neuronal plasticity and neurodegeneration.   
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5 Uniform reporting of biomarker studies in 
neurological disorders 
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5.1 Introduction 
 
Hopes to bring the vast array of post-genomic era biomarkers to the bedside 
have so far been disappointing. Experience in other specialities outside of 
neuroscience have shown that candidate markers which were initially promising 
have not stood the test of time 225; 226. The lack of rigorous study design, sub-
group analyses without adequately powered sample sizes, differences in 
methodology and analytical incompleteness have produced different and biased 
conclusions from scientific groups despite the rigour of the peer review process 
227; 228; 229; 230. Premature acceptance of poorly validated markers have resulted 
in numerous publications 231; 232; 233; which still require further confirmation, 
engendering translational attrition of biomarkers to clinical practice 234; 235. 
 
Advances in the fields of neuroscience, developmental neurobiology and 
discovery tools have revolutionised our understanding of the disease 
pathogenesis and pathophysiology affecting the nervous system. Specific 
examples include, beta amyloid and Tau protein in Alzheimer’s disease, 
inflammatory mediators in multiple sclerosis, inhibitory growth factors in spinal 
cord repair, and gene mutations in inherited neurological disorders to name but 
a few. Majority of these are process-specific biomarkers that provide a 
mechanistic understanding of the pathophysiology of the disease in question. 
More recently, there has been a growing interest in developing biomarkers for 
diagnosis, risk-stratification, prognostication, or assessing treatment response. 
As a result many biomarkers are available in the literature that appear feasible 
in theory but unrealised in practice. The problem arises when investigators try to 
reproduce the work, by which stage it becomes clear that the published work is 
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either unclear or inadequate in its methodology, there is dubious use of 
statistics or the particular statistical approach does not provide clinically relevant 
information, or simply that the biomarker is of no clinical value after performing 
a larger screen. To date, only Aβ and Tau in Alzheimer’s disease and several 
autoantibodies have reached a stage of universal acceptance, albeit after 
extensive and prolonged research 236; 237. To my knowledge no other biological 
markers have come close to surrogate end-point status in neuroscience. A 
framework is therefore needed to ensure that emerging biomarkers in 
neuroscience are developed from well-designed studies with clearly-defined 
methodology, analysis and commentaries, and are presented in a standardised 
manner. 
 
 The European Biomarkers in Multiple Sclerosis (BioMS-eu) consortium 
(http://www.bioms.eu/) is a collaborative network working towards improving the 
quality of biomarker research in MS, incorporating experts in the field of 
neuroscience with experience in the critical process of biomarker validation. The 
consortium has previously developed criteria for the standardisation of 
cerebrospinal fluid collection and biobanking 238. There are already several sets 
of published guidelines which deal specifically with different aspects of 
biomedical science, for instance REMARK (tumour marker prognostic studies) 
239, STARD (diagnostic accuracy) 240 and CONSORT (randomised control trials) 
241; but there are no official guidance for the reporting of early, exploratory 
biological research including work on potential surrogate end-points, treatment-
response biomarkers and diagnostic markers which focus on method 
development and validation.  
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5.2 Aims 
 
To develop guidelines that standardise the process of reporting biomarker 
studies in neuroscience; to make biomarker studies more uniform and 
transparent, in line with existing standards for reporting research in other areas. 
The formalised set of guidelines should provide a clear framework for the 
reporting of biomarker studies work from early, exploratory biological research 
including work on potential surrogate end-points, treatment-response 
biomarkers and diagnostic markers. Specifically the guidelines developed 
should address the major problem areas, such as: 
 
• Methodology 
• Method validation/robustness 
• Data extraction and statistics 
• Clinical translational value 
 
The guidelines were a coordinated effort between myself the BioMS-eu 
consortium and were developed as part of a compatible series; the first being “A 
consensus protocol for the standardisation of cerebrospinal fluid collection and 
biobanking” 238. 
 
5.3 Methods 
 
We used the definition of biomarker established by the NIH Biomarkers 
Definition Working Group (BDWG):  
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“Biological Marker (Biomarker) – a characteristic that is objectively measured 
and evaluated as an indicator of normal biologic processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention” 
 
“Clinical endpoint – a characteristic that reflects how a patient feels, functions 
and survives” 
 
“Surrogate endpoint – a biomarker that is intended to substitute for a clinical 
endpoint” 90.  
 
We also considered elementary standards for reporting biomarker work arising 
from key conferences (The Biomarker World Congress, Annual Biomarkers 
Congress) and Food and Drug Administration (FDA) regulatory 
recommendations (http://www.fda.gov). A checklist of items were created and 
circulated via email to all members of the BioMS-eu committee. The merits of 
including specific recommendations were discussed at the annual BioMS-eu 
meetings 2007 - 2010 between committee members (a list of the members is 
provided in the appendix) before finalisation. The importance, relevance and 
practicality of each of the items were deliberated over. The final format and 
wording of guidelines were decided after discussions between the scientific and 
steering committee members by email. 
 
The guidelines reflect the consensus of the BioMS-eu at the time of writing and 
should be viewed as only recommendations. They will be subject to change in 
the future based on new emerging evidence.  
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5.4 Results 
 
We started with a checklist of 61 items based on recommendations from 
previous published guidelines, biomarker publications and input from the 
scientific and steering committee of the BioMS-eu. This was later reduced to a 
final optimal format consisting of 10 main items, which are presented here 
(Table 5-1).  
 
Items were excluded on the basis of lack of generalisability to different types of 
biomarker research, items that were desirable but not essential, and those that 
were considered outside the remit of the guidance. The checklist is divided into 
introduction, materials and methods, results and discussion, reflecting the 
subheadings used in a scientific publication. A detailed commentary on 
individual items is given below. 
 
For studies in which the primary focus was the clinical trial, discovery 
biomarkers using proteomics or microarrays, or prognostic studies the use of 
existing published guidelines specifically for these purposes was recommended 
(a full list is provided in the appendix to Chapter 5). 
 
5.4.1 Commentary on the checklist items 
 
1-2. The introduction should be sufficient to describe scientific background and 
rationale i.e. the hypothesis, the biomarker(s) or its identification if relevant, 
mechanism of action and its intended use. 
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Note: pertinent information on surrogate status may not be available at an early 
stage, in which case references from other publications may be provided in 
support. 
 
3. This section should contain the study protocol. Detailed information on study 
or sample population (such as size and diversity) is encouraged. Techniques for 
calculating sample size should be mentioned here if used. Where samples from 
specific studies are used for analysis, reference the applicable study protocols. 
 
4. The study should conform to any applicable ethics review regulations. 
 
5. Refers to the primary outcome (i.e the study’s objective and the relevant 
biomarker(s)) and if applicable secondary outcome measures used in the study 
(e.g. imaging, neurophysiology, clinical scores (disability scales, patient-
reported outcome measures)). 
 
6. This section should contain a detailed description of the assay methods and 
pre-analytical and analytical parameters, and unless well recognised (e.g. 
ELISA) avoid using acronyms wherever possible. Please refer to the collection 
protocol for information on sample handling. Additional information on 
performance characteristics (testing environment, conformity to a recognised 
standard) would inform on whether the assay is appropriate for the intended 
use. 
 
7. This section should contain a description of the data analysis method(s) 
used, including methods for dealing with missing values and outliers where 
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applicable. When using more complex statistical models (e.g. mixed-effects in 
the study of repeated measures) provide a description of the model and 
including any assumptions made on the model components. 
 
8. We recommend that summary descriptions of the study or sample 
populations should be assembled in tabular format in order for any variances 
between the groups to be seen more readily. The table should include any 
variables that you think may influence the study outcomes (e.g. disease activity, 
disability score, smoking status etc.). Similarly, key experimental findings should 
be summarised in tables or graphs, together with a brief description of the 
results. 
 
9-10. This is the discussion section of the work. It should contain a summary 
description of the biomarker(s) characteristics, whether the study aims and 
objectives were met, if relevant, relationship to existing biomarkers, and 
intended use(s). It should also address limitations or variability due to 
pathophysiological, environmental or demographic factors. And finally, address 
areas for future work (e.g. a larger population based study, add-on study to 
clinical trials etc.). 
 
 
Figure 5-1 Summary guidance framework for the reporting of biomarker research. The 
framework follows a similar style to that of an original article and includes an introduction, 
materials and methods, results and discussion section for standardized reporting. 
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INTRODUCTION 
 
1. General introduction 
a. Details on scientific background and rationale. 
2. Specific introduction 
a. Identification of the biomarker and its expected role. 
b. The role or intended use of the biomarker (s). 
 
MATERIALS AND METHODS 
 
3. Include information on study or sample population  
a. Species, gender, age, disease/non-disease, disease stage, treatments, as well 
as use of specific cohorts (randomised control trial or cross-sectional and time-
course).  If relevant, include also reasons for sample exclusion. 
b. Type of sample – cerebrospinal fluid, plasma, serum etc 
c. Evidence of how sample size was calculated is desirable. 
4. State the ethical procedures adopted. 
5. Include a detailed account of outcome measures used, experimental as well as 
clinical end-points. 
6. Assay methods 
a. Include information on sample/reagent preparation and handling 
i. Pre-analytical parameters – use of serum separators, special 
precautions, storage (refer to collection protocols). 
ii. Analytical parameters (sample preparation; source of reference 
material or calibrants and antibodies; analytical specificity – linearity, 
and recovery; sensitivity – upper and lower limit of quantitation 
(LOQ), quality control measures – inter- and intra-assay coefficient 
of variation (CV), precision; potential interference – haemolysis, 
lipaemia, drugs etc) 
b. Provide adequate descriptions of any analytical techniques you have used 
including kits and type of platform. If you are using an existing method, you may 
cite the method as described previously. If you modify a method, you may cite 
the method, but must also describe the changes and reasons for them. 
c. Performance characteristics 
i. Performance in the testing environment where it will ultimately be 
used i.e. laboratory or bedside. 
ii. Cross-validation with other technologies or technique. 
7. Statistical analyses 
a. General 
i. Describe the statistical methods used, parametric vs. non-parametric 
analyses. Directly reference statistical packages and versions used. 
ii. P-values, median or mean, standard deviation or range should be 
used as standard.  
iii. Correct for multiple comparisons if required. 
b. Specific 
i. Describe properties of statistical models if used. 
ii. Use ROC curves to convey the performance characteristics of 
diagnostic markers if relevant. 
iii. Where applicable, provide information on the treatment of missing 
values and outliers. 
 
RESULTS 
8. Data analysis and presentation 
a. Show the summarized demographics of the study or sample population  
b. Present experimental data in tables or graphs as required together with a 
description of the results to aid interpretation. 
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5.5 Discussion 
 
There is an overriding need in biomedical research to find clinically useful 
biomarkers to inform regulatory and therapeutic decisions without the need for 
expensive and time consuming experimental work. However, many biomarkers 
have failed in their application and their high attrition has left many doubtful and 
cynical, with thoughts of biomarkers being desirable but not essential becoming 
more prevalent 234; 235; 242; 243. There is a growing need for standardised 
guidelines relating to every step of biomarker research representative of good 
experimental design with stringent criteria for data analysis and representation. 
 
The guidelines outlined here represent minimal criteria required for the reporting 
of biomarker studies, and represents a unifying approach to biomarkers in 
neurological disorders that are in line with guidelines already published for other 
experimental studies. The European BioMS Society hopes the provision of 
these guidelines will ultimately lead to the content of publications being high, 
thereby reinforcing and increasing confidence in biomarker research. 
 
. 
c. Biomarker specific characteristics 
i. Show data on the relationship between the biomarker(s) and existing 
prognostic measures.  
ii. Diagnostic biomarkers – sensitivity, specificity, PPV/NPV, receiver 
operating characteristic curve (ROC curve) and odds ratio, as 
appropriate. 
 
DISCUSSION 
9. A discussion of the results based on the original aims & objectives including any 
inferred clinical value. Discuss results in the context of comparable or similar 
previous studies. 
10. Address limitations, sources of potential bias and suggest areas for future work. 
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Guidance’s can now be found on many aspects of research (STARD, 
CONSORT, REMARK, PRISMA) and many journals require these as minimum 
reporting standards to be adhered to, making it easier for reviewers and editors 
to assess quality of work, but also for authors to view the standards and their 
justifications and provide a structure to their manuscript. Although there are 
existing guidance’s, none are specific for biomarker reporting per se which is 
currently left to the direction of the journal/reviewer and much more clarity is 
needed here. The reporting guidelines should be able to provide a framework 
wherein clear and transparent reporting of study aims, methods, outcome(s) 
and interpretation of the results can take place, reflecting particularly on 
possible problem areas. Proposed standards should be weighted in toward 
scientific validity with requirements that impose data integrity constraints to 
permit reproduction of scientific work. Its production should follow a style that is 
universally accessible to all journals across many disciplines; a manuscript style 
is therefore favoured. It is important however that they do not evolve into critical 
appraisal tools for evaluating study quality and remain as their title indicates 
reporting guidelines which are there to assist authors in writing good biomarker 
articles 244. Similarly, reporting guidelines should not stifle creativity in research 
but simply encourage clear explanations of individual decisions made in the 
study to provide clarity and completeness of reporting. 
 
With all of the above recommendations in mind the BioMS-eu committee have 
developed a minimum framework for reporting biomarker research not to be re-
produced at verbatim but to act as guides when preparing manuscripts. The 
development of comprehensive guidelines in practice is a continuous process 
and will be subject to change in the future based on new emerging evidence. 
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Ultimately, their value in reporting biomarker research will depend on how 
widely they are adopted by the scientific committee.  
 
In the course of this thesis I have aimed to provide a clear representation of the 
analytical methods and results using this framework that can be used to judge 
the quality, reliability and reproducibility of the findings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
148 
 
6 Concluding remarks and future directions 
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The observations made in this thesis point to one important over-riding 
conclusion about adult CNS plasticity and its capacity for repair for the first time 
that the author is aware of, that is guidance cues fundamental to axonal 
elongation and targeting is damaged during disease and fail to recover both in 
cell culture and in-vivo. Henceforth, abbreviating the potential for long-term 
recovery. Individuals most affected were those with primary neurodegenerative 
conditions, such as Alzheimer’s disease or disorders with an underlying 
neurodegenerative predisposition, such as multiple sclerosis and motorneurone 
disease. This has obvious clinical implications for the treatment of CNS axonal 
injury. This supplements previous work in this area about recovery from 
neuronal injury in the adult CNS. Certainly, work by Rolf et al. 176 supports this, 
demonstrating that the long axonal projections of the corticospinal tract (CST) 
are impaired in the absence of neural cell adhesion molecule and may not be 
capable of long-term survival, leading to disease progression.  
 
A key event in axonal recovery after injury is the elaboration of a growth cone – 
the motile tip that navigates the axon across the tissue substratum; which is 
preceded by induction of growth cone components, including GAP-43 and 
NCAM, that persist in the adult brain in regions of neuronal plasticity, making 
them the logical choice for measuring regenerative potential in the mature CNS 
59; 245; 246; 247. Higher vertebrates have to a greater degree lost their ability to 
regenerate CNS axons over the long-term during the course of evolution, unlike 
their anamniotic vertebrate (fish and amphibians) counterparts. Within the rat 
neuronal culture system there is a gradual repression in NCAM over time, with a 
failure to re-express more following injury. In experimental autoimmune 
encephalomyelitis (EAE), NCAM is lost precipitously irrespective of disease 
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type, whether it is relapsing-remitting (SJL mice) or a more chronic course 
without complete remissions (C57BL/6 mice). From this it may be inferred that 
repair in the CNS is hampered by two negative conditions: 1) the lack of reserve 
in the ageing nervous system; 2) the absence of growth cone trophic 
substances able to sustain longitudinal extension of interrupted nerve fibers. 
Epidemiological evidence from multiple sclerosis patients alludes to this 
possibility; with the finding that disability onset is age-dependent with younger 
onset reaching disability milestones earlier, not significantly affected by disease 
type, be it relapsing-remitting or progressive 188; 248. 
 
The existence of soluble forms of NCAM in blood, CSF and cell culture 
supernatants has long been known 75; 131; 142. Although, GAP-43 was originally 
isolated synaptic plasma membranes, it is also present in substantial quantities 
in the CSF, but not in blood. Whether they are actively secreted into 
extracellular space or released by detachment is difficult to ascertain. Although 
their constant level in subjects without significant neurological disease implies 
the existence of active secretion mechanism with the establishment of a 
dynamic equilibrium in the CSF. Previously soluble NCAM has been found to be 
present in culture medium before the appearance of membrane-associated 
NCAM on the cell surface, indicating that soluble NCAM contains a secreted 
component 75; 142. The exact role of both soluble NCAM and GAP-43 remains to 
be fully elucidated. Nonetheless, it may be plausible that they act as local 
trophic factors in the process of restorative neurogenesis, akin to 
neuroendocrine hormones involved in autocrine and paracrine signaling. 
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 A critical threshold value for NCAM expression that is required for increased 
neurite outgrowth has been demonstrated in neurons cultured on monolayers of 
cells expressing transfected NCAM. Above this threshold, even small increases 
in NCAM induced a significant increase in neurite outgrowth 249. An intriguing 
speculation would be whether parallels can be drawn from this work to soluble 
CSF NCAM levels where similar threshold values may in theory be in operation. 
It is then plausible that the low levels demonstrated in the neurodegenerative 
disorders are not conducive to neurite outgrowth, resulting in a reduced 
potential for recovery after injury. Some support for this concept is evidenced by 
the polarization in NCAM values between relapsing-remitting MS and secondary 
progressive MS. Although, GAP-43 measurements showed no such trend, it 
would be worthwhile reinvestigating the existence of a threshold value for 
neuronal responsiveness to GAP-43 in a larger sample size. Although 
Teunissen et al. have demonstrated that GAP-43 expression was found to be 
reduced in majority of white matter plaques in MS, this was independent of the 
lesion stage 111. 
 
These experiments have opened several avenues for investigating the impact of 
disease on neurons at a molecular level. If these findings are supported by 
future investigations, this has significant implications for being able to measure 
repair in the adult CNS and the notion of discovering possible targets for clinical 
intervention in the process is intuitively appealing. With this in mind areas for 
future work are considered below: 
 
1) Functional evidence to support a role for NCAM in repair and disability using 
NCAM-/- knock out mice. During development the overall brain architecture of 
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the knock outs is surprisingly normal with a mild phenotype that is puzzling 
considering the prominent role assigned to NCAM in regulating axonal growth. 
With Experimental autoimmune encephalomyelitis (EAE) we have found a 
severe drop in the NCAM content of spinal cords, and previous investigators 
have demonstrated hypoplasia of the corticospinal tract in adult NCAM-deficient 
mice – what then would be the result of inducing EAE in NCAM-/- mice?  This 
work will aim to dissect the molecular effects of inflammation/demyelination on 
axonal plasticity in the face of NCAM deficiency, and assess the effect on 
corticospinal tract function using real-time mobility measures (rota-rod) and 
disability scoring systems (EAE scoring system). 
 
2) NCAM immunoreactivity in acutely demyelinated plaques has been 
demonstrated to be greatly reduced, further work studying NCAM in various 
stages of the demyelinated MS plaque will favor a hypothesis of reduced 
plasticity in chronic MS.  
 
3) CSF NCAM and to some extent GAP-43 (although further clarification from 
in-vitro and in-vivo models is needed) have the potential to be used as 
prognostic biomarkers to assess the risk of disease progression in the context 
of neuroprotective clinical trials and can be used in patient stratification either at 
the beginning or end of the trial, thereby simplifying subsequent interpretation of 
the clinical findings and providing benchmarks for future trials.  
 
This would require adding a biological arm to longitudinal Phase II clinical trials 
with repeated lumbar puncture analysis. Our inability to measure these 
biomarkers in the blood reliably makes this the only viable option, cf. Tau and 
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Aβ measures in Alzheimer’s disease. Moreover, analysis performed during or 
right after treatment may provide mechanistic explanations for a drug’s action 
and its role in plasticity. 
 
4) Lastly, the precise role of soluble NCAM and GAP-43 in plasticity of the adult 
CNS is not well understood. It would be important with future experiments to 
address a) the mechanisms whereby these factors regulate cell adhesion and 
synaptic function, respectively, b) whether there is a critical threshold for 
neuronal responsiveness to soluble NCAM and GAP-43 and c) whether 
boosting their levels lead to improved repair/recovery following injury in the 
adult nervous system. 
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7 Appendix 
 
7.1 Chapter 2 
 
7.1.1 Polyacrylamide gel electrophoresis (PAGE) and ELISA: 
Buffers and solutions 
 
 
Product    Uses   Constituents, product 
no. 
 
NuPAGE MES SDS  Running buffer in PAGE 500mL (20x), pH of 1x  
buffer        solution is 7.3 
50mM MES, 50mM Tris                     
Base, 0.1% SDS, 1mM 
EDTA 
        #NP0002, Invitrogen 
 
NuPAGE LDS sample Sample solubilisation  10mL (4x) 
#NP0007, Invitrogen 
 
DL-Dithiothreitol (DTT), Reducing protein disulfide 1g 
Cleland’s reagent  bonds prior to PAGE #D0632, Sigma 
 
NuPAGE Transfer  Immunoblotting  500mL (20x), pH of 1x  
buffer        solution is 7.2  
        25mM Bicine, 25mM Bis-                                               
        Tris, 1mM EDTA,    
        0.05mM Chlorobutanol 
 
Methanol, CH3OH  Immunoblotting  2.5L GPR Rectapur 
        #20846.326, VWR 
   
Enhanced    Chemiluminescence 500mL SuperSignal   
chemiluminescent      West Pico   
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developing solution      Chemiluminescent   
       substrate  
      #34078, Thermo 
Scientific 
 
PBS solution   Binding, diluent and  Dry powder dissolved in  
wash solutions in ELISA 1L deionised water will 
yield 1M PBS, pH 7.4 
        #P5368, Sigma 
 
Supersensitive TMB Detection of antibody #T4444, Sigma 
substrate   reactivity in ELISA 
 
 
7.1.2 Proteomics buffers 
 
Product    Uses   Constituents, product 
no. 
 
BSA solution   Blocking buffer  0.1% BSA/1M PBS, pH  
        7.4 
        #A3294, Sigma 
 
Triton X-100 wash  Washing buffer  1M PBS with 0.1% Triton 
solution       X-100 
        #T9284, Sigma 
 
5mM ammonium  Removal of salts  0.3854g in 1L, pH 7.0  
acetate       (pH using solution of  
        ammonia or acetic acid,  
        never HCL or NaOH) 
        #A7330, Sigma 
 
Sinapinic acid matrix Matrix for MS  SPA in 50% ACN and  
        0.1% TFA 
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        #49508, Fluka 
 
ACN and formic acid Removal of proteins  70% ACN/0.2% TFA  
Solutions   from chips   followed by 50% formic  
        acid/25% ACN/15%  
        isopropanol/10%H2O 
 
7.2 Chapter 3 
7.2.1 D1 Solution 250 
All purchased from Sigma (UK) unless specified: 
138 mM NaCl 
5.4 mM KCl 
0.17 mM Na2HPO4 
0.22 mM KH2PO4 
5.55 mM D-glucose 
58.43 mM sucrose 
5 mg/L phenol red solution (Gibco BRL Life Technologies Ltd, UK) 
 
7.2.2 Aggregate media 
 
Serum free high glucose Dulbecco’s modified Eagle’s medium without sodium 
pyruvate (DMEM; Gibco BRL), supplemented with: 
0.8 μM bovine insulin 
Trace hormones, vitamins and elements 186 
100 U/mL penicillin (Gibco BRL) 
100 μg/mL streptomycin (Gibco BRL) 
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7.3 Chapter 4 
7.3.1 Purification recipes: native and denaturing conditions 
7.3.1.1 Buffer Stock Solutions (10x) 
Prepare sodium phosphate stock solutions as follows: 
Stock Solution A (10x) 
200 mM sodium phosphate, monobasic (NaH2PO4); #S0751 Sigma 
5 M NaCl; #S5886 Sigma 
Dissolve 27.6 g sodium phosphate, monobasic and 292.9 g NaCl in 900 mL of 
deionized water. Mix well and adjust volume to 1L with deionized water. Store 
solution at room temperature. 
 
Stock Solution B (10x) 
200 mM sodium phosphate, dibasic (Na2HPO4); #71284 Sigma 
5 M NaCl 
Dissolve 28.4 g sodium phosphate, dibasic and 292.9 g NaCl in 900 mL of 
deionized water. Mix well and adjust volume to 1L with deionized water. Store 
solution at room temperature. 
 
7.3.1.2 5x Native Purification Buffer, pH 8.0 
250 mM NaH2PO4 
2.5 M NaCl 
Prepare 200 mL solution as follows: 
1. To 180 mL deionized water, add  
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NaH2PO4               7 g 
NaCl           29.2 g 
2. Adjust pH with NaOH to pH 8.0 
3. Bring the final volume to 200 mL with water 
4. Store buffer at room temperature. 
 
7.3.1.3 3 M imidazole, pH 6.0 
3 M imidazole; #I202 Sigma 
500 mM NaCl 
20 mM Sodium phosphate buffer, pH 6.0 
 
Prepare 100 mL solution as follows: 
1. To 90 mL deionized water, add 
Imidazole         20.6 g 
Stock Solution A (10x)    8.77 mL 
Stock Solution B (10x)    1.23 mL 
2. Adjust pH to 6.0 with HCL or NaOH as necessary 
3. Bring the final volume to 100 mL with deionized water. If the solution 
forms a precipitate, heat the solution until the precipitate dissolves. 
4. Store buffer at room temperature. 
 
7.3.1.4 Native conditions 
 
1x Native Purification Buffer 
To prepare 100 mL 1x Native Purification Buffer: 
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 80 mL sterile distilled water 
 20 mL 5x Native Purification Buffer  
Adjust pH to 8.0 with NaOH or HCL. 
 
Native Binding Buffer 
Use 1x Native Purification Buffer as Native Binding Buffer. 
 
Native Wash Buffer 
To prepare 50 mL Native Wash Buffer with 20mM imidazole: 
 50 mL 1x Native Purification Buffer 
 335 μL of 3M Imidazole, pH 6.0 
Adjust pH to 8.0 with NaOH or HCL 
 
Native Elution Buffer 
To prepare 15 mL Native Elution Buffer with 250 mM imidazole: 
 13.75 mL 1x Native Purification Buffer 
 1.25 mL 3M imidazole, pH 6.0 
Adjust pH to 8.0 with NaOH or HCL. 
 
7.3.1.5 Denaturing conditions 
 
Denaturing Binding Buffer 
8 M urea 
50 mM NaCl 
20 mM sodium phosphate, pH 7.8 
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Prepare 100 mL solution as follows: 
1. To 90 mL deionized water, add 
Stock Solution A (10x)    0.58 mL 
Stock Solution B (10x)    9.42 mL 
Urea          48.1 g 
2. Stir the solution with gentle heating (50-60oC) until completely dissolved. 
When cooled at room temperature, adjust pH to 7.8 using NaOH or HCL. 
3. Bring volume to 100 mL. 
4. Store buffer at room temperature. 
 
Denaturing Wash buffer 
8 M urea 
500 mM NaCl 
20 mM Sodium phosphate, pH 6.0 
Prepare 100 mL solution as follows: 
1. To 90 mL deionized water, add 
Stock Solution A (10x)    7.38 mL 
Stock Solution B (10x)    2.62 mL 
Urea          48.1 g 
2. Stir the solution with gentle heating (50-60oC) until completely dissolved. 
Adjust pH to 6.0 using NaOH or HCL. 
3. Bring the volume to 100 mL. 
4. Store buffer at room temperature. 
 
Denaturing Elution Buffer 
8 M urea 
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500 mM NaCl 
20 mM Sodium phosphate, pH 4.0 
Prepare 100 mL as follows: 
1. To 90 mL deionized water, add 
Stock Solution A (10x)      10 mL 
Urea         48.1 g 
2. Stir the solution with gentle heating (50-60oC) until completely dissolved. 
Adjust pH to 4.0 using NaOH or HCL. 
3. Bring the volume to 100 mL. 
4. Store buffer at room temperature. 
NB: Filter steralise all buffers using a 0.45 μm filter (autoclaving the solution will 
alter the pH of the buffer). 
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CONSORT: 
Consolidated 
Standards of 
Reporting Trials 
Reporting of 
randomised 
control trials 
http://www.consort-statement.org/ 
EQUATOR: 
Enhancing the 
QUAlity and 
Transparency Of 
health Research 
For good 
reporting of 
health research 
studies 
http://www.equator-network.org/ 
MIAPE: The 
Minimum 
Information About a 
Proteomics 
Experiment 
Reporting 
guidelines for 
proteomics 
http://www.psidev.info/index.php?q=node/91 
MIBBI: Minimum 
Information of 
Biological and 
Biomedical 
Investigations 
For reporting 
aspects of 
biological and 
biomedical 
science 
http://www.mibbi.org/index.php/Main_Page 
MOOSE: Meta-
analysis of 
Observational 
Studies in 
Epidemiology 
Proposal for 
reporting meta-
analyses of 
observational 
studies in 
epidemiology 
Stroup,D.F. et al. JAMA. 2000 Apr 19; 283 
(15): 2008-12. Review. PubMed PMID: 
10789670 
PRISMA: Preferred 
Reporting Items for 
Systematic Reviews 
and Meta-Analyses 
Minimum set of 
items for 
reporting in 
systematic 
reviews and 
meta-analyses 
http://www.prisma-statement.org/ 
QUOROM: QUality 
Of Reporting Meta-
analyses 
Reporting meta-
analyses of 
randomised 
control trials 
http://www.consort-statement.org/ 
REMARK: Guidelines for McShane,L.M. et al. Breast Cancer Res. 
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REporting 
recommendations 
for tumor MARKer 
prognostic studies 
reporting tumour 
marker studies 
Treat. 2006 Nov; 100 (2):229-35. PubMed 
PMID: 16932852 
STARD: STAndards 
for the reporting of 
Diagnostic 
accuracy 
Reporting 
studies of 
diagnostic 
accuracy 
http://www.stard-statement.org/ 
STREGA: 
STrengthening the 
REporting of 
OBservational 
Studies in 
Epidemiology 
Guidelines to 
promote clear 
reporting of 
genetic 
association 
studies 
http://www.cdc.gov/genomics/hugenet/ 
workshops/strega.htm 
STROBE: 
STrengthening the 
Reporting of 
OBservational 
studies in 
Epidemiology 
Reporting of 
observational 
studies 
http://www.strobe-
statement.org/Support.html 
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